

# FUS Mislocalization Rewires a Cortical Gene Network to Drive Cognitive and Behavioral Impairment in ALS

Raphaëlle CASSEL<sup>1</sup>, Félicie LORENC<sup>1</sup>, Aurélie BOMBARDIER<sup>1</sup>, Claudia DE TAPIA<sup>1</sup>, Stéphane DIETERLE<sup>1</sup>, Cláudio GOUVEIA ROQUE<sup>2</sup>, Christopher A. JACKSON<sup>2</sup>, Geoffrey STUART-LOPEZ<sup>1</sup>, Caroline ROUAUX<sup>1</sup>, Simon J. GUILLOT<sup>1</sup>, Marie-Christine BIRLING<sup>3</sup>, Pascal KESSLER<sup>4</sup>, Maurizio GRASSANO<sup>5</sup>, Bryan TRAYNOR<sup>6,7,8,9</sup>, Adriano CHIO<sup>5</sup>, Raju ROY<sup>10</sup>, James SHORTER<sup>10</sup>, Fergal M. WALDRON<sup>11</sup>, Jenna M. GREGORY<sup>11</sup>, Hemali PHATNANI<sup>2,12</sup>, Luc DUPUIS<sup>1,13\*</sup>, Salim MEGAT<sup>1,13\*\*</sup>

- 1 Université de Strasbourg, Inserm, Strasbourg Translational Neuroscience and Psychiatry, UMR-S1329, Centre de Recherches en Biomédecine; Strasbourg, France
- 2 Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013, USA
- 3 PHENOMIN-Institut Clinique de la Souris, Université de Strasbourg, Illkirch, France
- 4 Université de Strasbourg, INSERM, UMS 38, Imaging Core Facility PIC-STRA, CRBS, Strasbourg, France.
- 5 ALS Center “Rita Levi Montalcini” Department of Neuroscience, University of Turin, Turin, Italy.
- 6 Neuromuscular Diseases Research Section, National Institute on Aging (NIA), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- 7 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- 8 NINDS, NIH, Bethesda, MD 20892, USA.
- 9 ASO Therapeutics Laboratory, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA.
- 10 Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
- 11 Institute of Medical Sciences, University of Aberdeen, UK.
- 12 Department of Neurology, Center for Translational and Computational Neuroimmunology, Columbia University, New York, NY 10032, USA

13 Equal contribution.

\* correspondence: [ldupuis@unistra.fr](mailto:ldupuis@unistra.fr)

\*\* correspondence: [salim.megat@inserm.fr](mailto:salim.megat@inserm.fr)

Lead contact: Luc DUPUIS, [ldupuis@unistra.fr](mailto:ldupuis@unistra.fr)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 **Summary**

44 (149 words)

45

46 Cognitive and behavioral impairment affects up to half of individuals with amyotrophic lateral  
47 sclerosis (ALS), but their molecular origin remains unresolved. Here, we identify  
48 mislocalization of the RNA-binding protein FUS in cortical neurons as a defining feature in ALS  
49 patients with cognitive impairment (ALS-ci). Selective mislocalization of FUS in adult cortical  
50 projection neurons in mice is sufficient to trigger ALS-ci- and ALS with behavioral impairment  
51 (ALS-bi)-like phenotypes, including deficits in sociability, and neurodegeneration. Single-  
52 nucleus transcriptomics reveal a conserved FUS-dependent gene network downregulated in  
53 these mice and ALS-ci patients. This regulon is enriched for ALS genetic risk factors and newly  
54 implicates *FBXO16* in ALS-bi. Carriers of protein-truncating *FBXO16* variants display  
55 behavioral abnormalities, frontotemporal atrophy, and increased levels of dementia-linked  
56 biomarkers. These findings define a neuron-intrinsic mechanism for cognitive and behavioral  
57 dysfunction in ALS and nominate FUS mislocalization and its downstream gene network as  
58 therapeutic targets.

59


60 **Keywords**

61 Amyotrophic lateral sclerosis, fronto-temporal dementia, cognitive impairment, behavioral  
62 impairment, mouse models, genetics, single cell biology.

63

64 **Graphical abstract**

65



66

67

68 **Highlights**

69

70

71

72

73

74

75

76

77

78

79

80

81

- Transcriptional fingerprint of FUS mislocalization is observed in cortical projection neurons of ALS patients
- FUS mislocalization leads to downregulation in cortical projection neurons of a cross-species conserved regulon shared with TDP43
- FUS mislocalization in adult cortical projection neurons is sufficient to trigger ALS related cognitive and behavioral impairment in mouse models
- FUS is mislocalized and the FUS regulon is downregulated in ALS patients with cognitive impairment
- The FUS regulon is enriched in genetic risk factors for cognitive and behavioral impairment in ALS
- Carriers of protein truncating variants of *FBXO16*, one of the FUS regulon genes, display behavioral, imaging and biochemical markers of ALS with behavioral impairment.

## 82 Introduction

83  
84 Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset disease of motor neurons.  
85 ALS is characterized by the onset of motor symptoms in the 5<sup>th</sup> or 6<sup>th</sup> decade of life, rapidly  
86 progressing to fatal paralysis, usually within two to three years after symptoms' onset. A  
87 substantial fraction of ALS patients (up to 50%) develop additional symptoms, unrelated to the  
88 motor system, in particular variable cognitive impairment (ALS-ci) or behavioral impairment  
89 (ALS-bi), with some patients even presenting with frontotemporal dementia (ALS-FTD)  
90 (Abrahams, 2023). The relevance of this ALS-FTD clinical continuum is substantiated by the  
91 existence of a common pathology between ALS and FTD, in particular aggregates of TDP-43,  
92 an RNA-binding protein (RBP), as well as common genetic associations (Goutman et al.,  
93 2022a, b). It remains unclear, however, whether ALS-ci, ALS-bi and ALS without cognitive  
94 impairment have distinct mechanisms. Indeed, TDP-43 pathology in areas involved in  
95 cognition, behavior and executive functions is a poor predictor of ALS-ci or ALS-bi (Bampton  
96 et al., 2024; Rifai et al., 2024; Suzuki et al., 2024), suggesting that additional pathways  
97 contribute to the development of these extra-motor deficits.

98  
99 An attractive hypothesis would be that other, yet undetermined, pathological features develop  
100 in ALS-ci or ALS-bi patients but not in patients without cognitive or behavioral impairment, to  
101 cause the ci/bi phenotypes. As a matter of fact, the co-occurrence of several proteinopathies  
102 is frequent in neurodegenerative diseases, and is generally associated with worsened  
103 prognosis (Irwin et al., 2017; James et al., 2016; Karanth et al., 2020; Katsumata et al., 2020;  
104 Robinson et al., 2023). Interestingly, the heritability of ALS is enriched in TDP-43 targets  
105 (Brown et al., 2022; Ling et al., 2015; Ma et al., 2022; Megat et al., 2023). Beyond TDP-43, the  
106 heritability of ALS is also enriched in targets of another RBP linked to ALS, FUS (Megat et al.,  
107 2023). Mutations in the *FUS* gene cause severe familial ALS cases through altered nuclear  
108 import of the FUS protein (Kwiatkowski et al., 2009; Moens et al., 2025; Scekcic-Zahirovic et  
109 al., 2017; Scekcic-Zahirovic et al., 2016; Vance et al., 2009). FUS aggregates are also observed  
110 in a subset of FTD cases, in complex aggregates that also include TAF15 and other RBPs  
111 (Mackenzie et al., 2011a; Mackenzie et al., 2011b; Neumann et al., 2011; Urwin et al., 2010).  
112 Importantly, FUS is also mislocalized in the cytoplasm of neurons in sporadic ALS, even in the  
113 absence of obvious FUS aggregates (Tyzack et al., 2019; Tyzack et al., 2021), as well as in  
114 *C9ORF72* ALS (Rifai et al., 2022). Despite these observations, the distribution of FUS  
115 mislocalization across ALS, ALS-ci and ALS-bi patients remains unknown, and the  
116 consequences of FUS mislocalization on ALS clinical features, including cognitive and  
117 behavioral, are poorly characterized.

118  
119 Here, we demonstrate that FUS mislocalization in cortical neurons is more pronounced in ALS-  
120 ci than in ALS patients. Furthermore, FUS mislocalization in adult projection neurons is  
121 sufficient to lead to ALS-ci/bi-like phenotypes in mice. Through integration of various single-  
122 cell datasets, we identify a gene module downstream of FUS mislocalization that is  
123 downregulated in cortical neurons of ALS-ci patients and identify genetic associations between  
124 *FBXO16* and *WWOX*, two genes of this module, with ALS-bi and ALS-ci respectively. Thus,  
125 FUS mislocalization in projection neurons compromises expression of a gene network  
126 underlying the risk of cognitive and behavioral impairment in ALS.  
127  
128

## 129 Results

130

### 131 Mislocalization of FUS is sufficient to recapitulate transcriptomic alterations in ALS 132 excitatory projection neurons

133 Previous studies have observed mislocalization of FUS in neurons of sporadic and familial ALS  
134 patients, including *C9ORF72* (Rifai et al., 2022; Tyzack et al., 2019; Tyzack et al., 2021), but  
135 did not define downstream transcriptional consequences. To identify those alterations, we  
136 generated a single-nuclei RNA sequencing (snRNAseq) dataset of the frontal cortex of  
137 *Fus*<sup>ΔNLS/+</sup> mice. This mouse model is a knock-in mouse model expressing a FUS protein  
138 truncated of its C-terminal nuclear localization sequence (NLS). This leads to the cytoplasmic  
139 accumulation of FUS (Scekic-Zahirovic et al., 2017; Scekic-Zahirovic et al., 2016), without  
140 aggregation. Similar mutations have been documented in ALS patients, and the cytoplasmic  
141 accumulation of FUS without aggregation is similar to what has been reported in ALS patients  
142 (Rifai et al., 2022; Tyzack et al., 2019; Tyzack et al., 2021). We used this novel dataset as a  
143 blueprint of FUS mislocalization and compared it with a publicly available dataset of motor  
144 cortex of ALS patients (Pineda et al., 2024) (**Figure 1A-B**). Single nuclei RNA sequencing of  
145 frontal cortex of *Fus*<sup>ΔNLS/+</sup> mice yielded 78,514 nuclei allowing the identification of 21 clusters  
146 that reflect large cellular subtypes as previously described in the mouse primary motor cortex  
147 (Network, 2021). Analysis of human snRNAseq from the motor cortex yielded 156,545 nuclei  
148 split across 19 subclasses that allow the identification of the major cellular subtypes such as  
149 upper and deep layer excitatory neurons, interneurons derived from the medial and caudal  
150 ganglionic eminences, as well as different types of non-neuronal cells such as microglia,  
151 astrocytes and endothelial cells (**Figure 1C-D**). Principal component analysis of *Fus*<sup>ΔNLS/+</sup> mice  
152 and ALS patients showed strong transcriptional differences among excitatory projection  
153 neurons that is confirmed with a higher number of differentially expressed (DE) genes  
154 compared to inhibitory neurons and non-neuronal cells (**Figure 1C-D**). Gene ontology analysis  
155 performed on the overlapped DE genes in excitatory neurons in *Fus*<sup>ΔNLS/+</sup> mice and ALS  
156 patients show a similar enrichment in terms associated with mitochondrial function, RNA  
157 binding and mRNA translation (FDR<0.05) suggesting a common underlying mechanism  
158 driving neurodegeneration in human ALS patient and *Fus*<sup>ΔNLS/+</sup> mice. These results show that  
159 endogenous mislocalization of FUS leads to similar transcriptional alterations as ALS  
160 specifically in cortical projection neurons (CPNs) (**Figure 1E-F**).

161

### 162 A conserved FUS regulon shared with TDP-43 in ALS-vulnerable neurons

163 FUS is an RNA binding protein with a prion-like domain and thousands of RNA targets (Lagier-  
164 Tourenne et al., 2012; Rogelj et al., 2012). To narrow down to the critical RNA targets  
165 associated with ALS, we reasoned that the genes of interest should (i) be modulated by FUS  
166 in CPNs and (ii) show similar alterations in mouse models and ALS patients. To integrate gene  
167 expression changes in a systems-level framework, we performed a co-expression analysis  
168 across available mouse and human datasets to identify significant co-expressed modules,  
169 using single-cell transcriptome of human L5 extra-telencephalic (L5-ET) vulnerable neurons  
170 (Pineda et al., 2024) and single-nuclei transcriptome of *Fus*<sup>ΔNLS/+</sup> mice (**Figure 2A-B**). We  
171 identified a total of 4 gene modules with signed correlation to ALS in either L5-ET human  
172 neurons, or *Fus*<sup>ΔNLS/+</sup> transcriptome, or both. Only one module, color coded “Turquoise”,  
173 showed correlation to ALS in both mouse and human species (**Figure 2B-E**). Specifically, the  
174 “Turquoise” module was downregulated in both human and mouse datasets (FDR <0.05)  
175 (**Figure 2E**). As we assume the module to be regulated through a FUS-dependent mechanism,  
176 we decided to name this module “FUS regulon” (**Table S1**). Gene ontology of the FUS regulon  
177 showed enrichment in genes involved in functions altered in ALS, e.g. cilium organization (De  
178 Decker et al., 2025), cytoskeleton or RNA binding (Brown and Al-Chalabi, 2017) (FDR<0.05)  
179 (**Figure 2F**). Downregulation of the FUS regulon was widespread across CPN in *Fus*<sup>ΔNLS/+</sup> mice  
180 as shown in **Figure 2G** using eigengene of the FUS regulon as a global measurement of FUS

181 regulon expression. For instance, the FUS regulon was downregulated in L5-PT neurons  
182 (grouping most extra-telencephalic neurons in mice) (unadjusted- $p = 0.040$ ), but also in L5-IT  
183 (intra-telencephalic neurons) (\*Bonferroni corrected- $p < 0.05$ ) in *Fus*<sup>ΔNLS/+</sup> mice (**Figure 2G**).  
184 Downregulation of the FUS regulon was significant in L5-ET neurons of the motor cortex of  
185 sporadic ALS patients (\*Bonferroni corrected- $p < 0.05$ ) (**Figure 2H**). To determine the  
186 specificity of the FUS regulon towards FUS among other RBPs, we evaluated expression of  
187 the FUS regulon in a publicly available dataset (Van Nostrand et al., 2020) that explored  
188 transcriptional effects of downregulation of 217 RBPs (**Figure 2I**). In this dataset, FUS ranked  
189 8<sup>th</sup> in RBPs downregulating the FUS regulon (**Table S2**). Interestingly, TDP-43 ranked 2<sup>nd</sup> as  
190 RBP with the most downregulation of the FUS regulon, suggesting that FUS and TDP-43 are  
191 both necessary for strong expression of the FUS regulon. Consistent with this, knockdown of  
192 TDP-43 in iPSC-derived motor neurons (Brown et al., 2022) led to decreased expression of  
193 the FUS regulon (\*\* $p < 0.01$ ) (**Figure 2J**), and expression of the FUS regulon was decreased in  
194 TDP-43 negative neuronal nuclei as compared to TDP-43 positive nuclei in FTD-TDP43  
195 patients samples (\*\* $p < 0.001$ ) (Liu et al., 2019) (**Figure 2K**). These results demonstrate that  
196 FUS mislocalization leads to downregulation of the FUS regulon in CPNs, phenocopying  
197 transcriptional alterations in vulnerable neurons in patients and is associated with FUS and  
198 TDP43 loss of function.

199

### 200 **Adult-onset FUS mislocalization in mouse cortical projection neurons reproduces** 201 **molecular, pathological and electrical alterations of ALS patients**

202 As the transcriptional consequences of FUS mislocalization were most prominent in CPNs, we  
203 then sought to restrict FUS mislocalization in adult excitatory projection neurons in a mouse  
204 model. Thus, we generated a novel mouse *Fus* allele allowing conditional ablation of the  
205 nuclear localization signal (NLS), leading to cytoplasmic accumulation of FUS. We engineered  
206 the *Fus* locus to insert loxP sequences in intron 12 and downstream of exon 15 (**Figure S1A**).  
207 The second loxP site is followed by a cDNA encoding exons 13 and 14 of *Fus*, followed by 3  
208 transcriptional stop cassettes and a poly-adenylation signal to restore exons 13 and 14 after  
209 CRE recombination (**Figure S1A**). Thus, CRE-mediated recombination is expected to delete  
210 exon 15 leading to a FUS protein without NLS, and thus to the same mutant FUS protein as in  
211 constitutive *Fus*<sup>ΔNLS/+</sup> mice. Germ line transmission of the recombinant allele was obtained and  
212 mice heterozygous and homozygous for the targeted allele will hereafter be referred to as  
213 *Fus*<sup>exon15</sup>. We first sought to validate the functionality of the new allele. To this end, primary  
214 cortical neurons of homozygous *Fus*<sup>exon15</sup> mice were transduced with CRE using an adenoviral  
215 vector (Ad-CRE). We observed Ad-CRE dose-dependent recombination of the *Fus* locus  
216 (**Figure S1B**), as well as decreased immunoreactivity to NLS FUS antibody (**Figure S1C**). To  
217 specifically mislocalize FUS in adult projection neurons, we crossed *Fus*<sup>exon15</sup> mice with  
218 transgenic mice expressing tamoxifen-inducible CRE specifically in excitatory projection  
219 neurons (Thy1<sup>CRE-ERT2</sup> mice (Young et al., 2008)). These mice also express YFP from the same  
220 construct allowing the unambiguous identification of targeted cells (Young et al., 2008).  
221 Through two cross-breeding steps we generated Thy1<sup>CRE-ERT2</sup>/*Fus*<sup>exon15</sup> mice, either  
222 homozygous or heterozygous for *Fus*<sup>exon15</sup>. Control mice were littermate *Fus*<sup>exon15</sup> homozygous  
223 mice, devoid of Thy1<sup>CRE-ERT2</sup> transgene. All mice underwent 5 days of Tamoxifen gavage at 6  
224 weeks of age and molecular analyses were performed 10 weeks after the induction of  
225 recombination (**Figure 3A**). Genotyping showed that a fraction of the *Fus* allele was efficiently  
226 recombined (**Figure S2A**). This recombination led to increased total *Fus* mRNA (**Figure S2B**)  
227 and mutant *Fus* mRNA as detected using RT-qPCR (**Figure S2C**). Moreover,  
228 nuclear/cytoplasmic fractionation followed by western blotting showed decreased  
229 immunoreactivity of FUS using an antibody targeting the C-terminal NLS, as well as increased  
230 cytoplasmic levels of FUS using an antibody recognizing the N-terminal domain in cortical  
231 extracts of Thy1<sup>CRE-ERT2</sup>/*Fus*<sup>exon15</sup> mice (**Figure 3B-C**). Moreover, we observed increased  
232 cytoplasmic FUS staining when using an antibody targeting N-terminal FUS (**Figure 3D**) while  
233 FUS NLS immunoreactivity disappeared in YFP-positive (hence recombined) cells in the

234 frontal cortex (**Figure S3A**, quantified in **Figure S3B**). Lastly,  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  cortex  
235 showed hallmarks of FUS dysfunction as illustrated by an upregulation of *Taf15* (**Figure S4A**),  
236 as well as decreased inclusion of introns 6 and 7 of the *Fus* gene or of *Sfpq* intron 9 (**Figure**  
237 **S4B-D**), all of which are previously documented molecular alterations downstream of FUS  
238 mislocalization (Humphrey et al., 2020; Luisier et al., 2018; Sanjuan-Ruiz et al., 2021; Tyzack  
239 et al., 2019; Tyzack et al., 2021). As a whole, these results show that the recombination was  
240 efficient, and led to the mislocalization of FUS selectively in CPNs.

241  
242 Having established an animal model with isolated FUS mislocalization in adult CPNs, we first  
243 sought to determine whether this intervention recapitulated the gene expression fingerprint  
244 observed in both patients and  $\text{Fus}^{\text{ANLS/+}}$  mice. We performed high-depth bulk RNA sequencing  
245 in the frontal cortex of  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice and control mice 2.5 months after  
246 recombination, which showed strong downregulation of the FUS regulon eigengenes (**Figure**  
247 **3E**). Beyond the FUS regulon eigengenes, we identified 1127 differentially expressed (DE)  
248 genes between  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice and controls (FDR <0.05) (**Figure S5A**) that were  
249 mostly related to neuronal projection and synapses (**Figure S5B-C**). Consistent with altered  
250 synaptic and electrical activity,  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice developed increased spike event  
251 activity as recorded upon longitudinal electrocorticography at 12 and 20 weeks of age (i.e. 6  
252 and 14 weeks after tamoxifen) (**Figure 3F-G**). We then counted NeuN-positive neurons 10  
253 weeks after recombination in both frontal and motor cortex using semi-automated counting  
254 procedures (**Figure 3H**) and observed a significant loss of neurons in both regions (**Figure 3I-**  
255 **K**). Thus, adult-onset mislocalization of FUS triggers molecular and electrical alterations, as  
256 well as neuronal loss observed in ALS patients.

### 257 258 **Adult-onset FUS mislocalization in cortical projection neurons phenocopies ALS-ci** 259 **and ALS-bi**

260 We did not observe weight loss or decreased motor performance in the inverted grid and grip  
261 tests conducted in  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice (**Figure S6A-D**, **Figure S7A**). Consistent with  
262 preserved motor function, lower motor neurons counts were unaltered despite efficient FUS  
263 mislocalization in these cells (**Figure S6E-G**). As ALS is also associated with impaired  
264 cognitive and behavioral function in ALS-ci and ALS-bi patients (Abrahams, 2023), we  
265 evaluated executive functions in  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice (**Figure 4A**). We observed that  
266  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice displayed a lower mean score and a higher number of untorn  
267 cotton pieces when building their nests as compared to control mice (**Figure 4B-C**), suggesting  
268 that the truncation of FUS in adult CPNs of mice leads to difficulties in planning, or planning  
269 and executing the successive steps involved in nesting. To assess the general sociability and  
270 interest in social novelty of  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice, we then performed the three-chamber  
271 test six weeks after induction of recombination. We first assessed the social preference of mice  
272 by presenting them a cage containing a mouse and an empty cage, and by measuring the time  
273 spent touching and sniffing them. We observed, as expected, that control mice spent  
274 significantly more time with the mouse (**Figure 4D**, solid black line) than with the empty cage  
275 during the first two trials (**Figure 4D**, dotted black line). This was also true for  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$   
276 mice but they showed significantly less interest than the control mice (**Figure 4D**, solid  
277 *versus* dotted blue lines). We then assessed social memory of mice by presenting them a  
278 known mouse (i.e. the one already met during the social preference phase of the test) and a  
279 novel mouse. We observed that the contacting time of  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice with the  
280 novel mouse was significantly lower compared to that of control mice ( $p < 0.001$ ). As a  
281 consequence, the recognition index was significantly decreased (towards chance level)  
282 compared to that of control mice (**Figure 4E-F**). These results were replicated in another  
283 paradigm, the resident intruder test (**Figure 4G-H**), thus highlighting impairments in social  
284 functions, and in particular decreased social interest, in  $\text{Thy1}^{\text{CRE-ERT2}}/\text{Fus}^{\text{exon15}}$  mice.  
285 Contrastingly, adult neuronal FUS mislocalization was not sufficient to trigger general memory  
286 defects as evidenced by an unaltered short-term or long-term object recognition (**Figure 4I-J**).

287 Importantly, these mice did not suffer from generalized anxiety (**Figure S7B-D**) or lack of  
288 motivation (**Figure S7E-G**) that could explain sociability alteration. Thus, adult onset  
289 mislocalization of FUS in CPNs selectively impairs executive function, social interaction and  
290 social memory but preserves motor function or novel object recognition task. In all, adult onset  
291 mislocalization of FUS in CPNs provides a mouse phenocopy of ALS-ci/bi patients in the  
292 absence of motor symptoms.

### 294 **FUS pathology and downregulation of the FUS regulon in patients with ALS-ci**

295 Our results in mice provided a causal link between cytoplasmic FUS mislocalization and  
296 cognitive and behavioral impairment. We then sought to determine whether this relation could  
297 be observed in ALS-ci patients. To this aim, we selected 6 deeply clinically  
298 phenotyped *C9ORF72* cases with post-mortem tissue paired with regional cognitive scoring  
299 performed for that functional domain. We selected BA39 as a language processing brain region  
300 that had been assessed during life using the Edinburgh Cognitive ALS Screening (ECAS) tool.  
301 Cases were stratified into ALS-ci (ECAS language domain score  $\leq 26$ ) and ALS (ECAS  
302 language domain score  $>26$ ) based on published diagnostic cutoffs. Cases with ALS-ci  
303 exhibited evidence of FUS pathology (cytoplasmic and nuclear pathology) (**Figure 5A**), which  
304 was less frequently encountered in ALS cases that were cognitively intact (**Figure 5B-C**).  
305 Indeed, FUS pathology, quantified using digital burden scoring (Rifai et al., 2022) correlated  
306 with ECAS score in this region scale (**Figure S8**) demonstrating that the burden of FUS  
307 pathology, measured in a non-biased way, correlates with cognitive function in these cases.  
308 To provide orthogonal evidence of altered FUS function in ALS-ci, we re-analyzed our dataset  
309 of snRNAseq in ALS and ALS-ci patients in frontal regions BA44 and BA46 (Petrescu et al.,  
310 2025) and merged this dataset with previously published BA4 and BA9 regions involved in  
311 motor control (Pineda et al., 2024). We identified 287,275 excitatory neurons and, among those  
312 1,547 L5-ET neurons, that expressed typical L5-ET expression markers such as *ADRA1A*,  
313 *POU3F1*, *VAT1L* and *SULF2* (**Figure 5D-E**). Merging the two datasets revealed two L5-ET  
314 subtypes, with their own expression markers (**Figure 5E**) and different distributions across  
315 cortical regions studied (**Figure 5F**). Importantly, we observed a diminished proportion of L5-  
316 ET neurons, but not L5-IT neurons, in ALS, and even more in ALS-ci patient (**Figure 5G-H**) in  
317 these datasets, further confirming the selective involvement of this neuronal population in ALS  
318 and ALS-ci. Importantly, expression of the FUS regulon was significantly downregulated in L5-  
319 ET and L5-IT neurons of ALS-ci patients as compared to controls (**Figure 5I**). ALS patients  
320 showed an intermediate situation with decreased expression of the FUS regulon only in L5-IT  
321 neurons (**Figure 5I**). This relationship between cognitive impairment and FUS regulon  
322 expression in L5-ET neurons was also observed at the individual patient level (**Figure 5J**) and  
323 there was a positive correlation between FUS regulon expression in L5-ET neurons and total  
324 ECAS scores of studied patients (**Figure 5K**). Strikingly, this relationship was mostly observed  
325 in BA46, involved in executive function, as compared to BA44 (**Figure 5L**). Last, we sought to  
326 determine whether cognitive function and FUS dysregulation could be related to an  
327 accumulated genetic burden of dementia. To answer this question, we processed whole  
328 genome-sequencing of patients with ALS and ALS-ci (Petrescu et al., 2025), and filtered out  
329 gene variants involved in dementia to compute a genetic burden that could be correlated with  
330 FUS regulon expression and cognitive function (**Figure 5M**). Indeed, a high genetic burden  
331 ( $>2$  missense variants) was associated with decreased ECAS score (**Figure 5N**) and, at the  
332 individual patient level, ALS-ci patients showing a higher genetic burden (**Figure 5J**).  
333 Accumulation of deleterious missense variants led to decreased cognitive performance in  
334 executive, language or memory subscores (**Figure 5O**). Consistently, expression of the FUS  
335 regulon was negatively correlated to genetic burden of dementia (**Figure 5P**). In all, our results  
336 suggest that ALS-ci develops in ALS patients with increased genetic burden of dementia,  
337 leading to cytoplasmic FUS mislocalisation and decreased expression of FUS downstream  
338 target genes in L5-ET vulnerable neurons.

340 **The FUS regulon is enriched in ALS genetic risk and allows for prioritizing novel ALS-**  
341 **ci/bi genes**

342 Our previous results provided indirect evidence that FUS and its regulated genes might lie in  
343 the same genetic pathway than other dementia related genes. Interestingly, the heritability of  
344 ALS is enriched in FUS binding sites (Megat et al., 2023). We thus hypothesized that the FUS  
345 regulon could be enriched in ALS-risk genes, and we applied stratified linkage disequilibrium  
346 (Bulik-Sullivan et al., 2015) (LD) score regression (S-LDSC) to the most recent ALS genome-  
347 wide association study (GWAS)(van Rheenen et al., 2021) (**Figure 6A**). We compared ALS  
348 heritability estimates in FUS regulon gene to a randomly sampled gene set over 10 iterations  
349 and used ALS GWAS data as a positive control. As shown in **Figure 6B**, FUS regulon genes  
350 are enriched in ALS heritability ( $E=87.7$  fold, \*Bonferroni  $p < 0.05$ ). As expected, we observed  
351 a strong enrichment of the ALS GWAS ( $E=387.3$  fold, \*Bonferroni  $p < 0.05$ ) but no enrichment  
352 in the randomly sampled gene set (Bonferroni  $p > 0.05$ ). These results suggest that the FUS  
353 regulon is highly enriched in ALS heritability and might contain new potential ALS genes. Then,  
354 we sought to refine our analysis through the comparison of the FUS regulon with genes known  
355 to cause ALS, ALS-FTD or pure FTD. When overlapping genes in the FUS regulon with a  
356 curated list of ALS genes, we observed a significant enrichment of genes involved in ALS-  
357 FTD, including (*FUS*, *KIF5A*, *C9ORF72*, *ERBB4*, *HTT* or *GBA*) (Fisher's exact test;  $p=2.2 \cdot 10^{-06}$ ) (**Figure 6C**).

359  
360 Having shown that FUS regulon expression is altered in ALS-ci and is enriched in ALS-FTD  
361 risk genes we sought to test whether the FUS regulon could help us prioritizing new genetic  
362 risk factors associated with either ALS-ci or ALS-bi. To do so, we analyzed whole genome  
363 sequences (WGS) from 546 ALS patients of the Answer ALS cohort who have been evaluated  
364 for cognitive and behavioral impairment through questionnaire screening according to ALS  
365 cognitive Behavioral Screen (ALS-CBS) scale (**Figure 6D**) (Baxi et al., 2022). WGS SNPs were  
366 filtered to map FUS regulon genes resulting in a final set of 131,202 SNPs falling onto at least  
367 one gene of the FUS regulon. Interestingly, we observed that rs11991627 located in the  
368 *FBXO16* gene is significantly associated with the risk of ALS-bi (Logistic regression:  $OR = 3.22$   
369 ( $1.94-4.23$ )  $p=5.44 \cdot 10^{-07}$ ) while it does not associate with ALS-ci (Logistic regression:  $OR =$   
370  $1.30$  ( $0.16-2.45$ )  $p=0.098$ ) (**Figure 6E-H**). Conversely, we observed a suggestive association  
371 of rs12324967 in the *WWOX* gene, previously associated with cognitive impairment in  
372 Parkinson's disease (Liu et al., 2021), with ALS-ci (Logistic regression:  $OR = 0.28$  ( $0.03-1.43$ )  
373  $p=5.08 \cdot 10^{-05}$ ) (**Figure 6E-H**). The rs11991627 allele in *FBXO16* shows an additive effect on  
374 behavioral score (One-way ANOVA:  $***p=1.31 \cdot 10^{-06}$ ), suggesting that *FBXO16* rs11991627  
375 carriers have increased risk of behavioral impairments associated with diagnosed ALS (**Figure**  
376 **6I**). These results show that the FUS regulon includes novel genes associated to cognitive  
377 and/or behavioral impairment in ALS, including *FBXO16* or *WWOX*.

378  
379 ***FBXO16* PTV carriers show behavioral abnormalities, fronto-temporal atrophy and**  
380 **increase expression of fluid biomarkers associated with dementia.**

381 We then sought to independently validate whether variants in *FBXO16* could represent risk  
382 factors for ALS-FTD related cognitive impairment. To this end, we leveraged large-scale UK  
383 Biobank data (Sudlow et al., 2015). In UK Biobank, we identified carriers of *FBXO16* protein-  
384 truncating variants (PTV) and tested whether these individuals displayed behavioral, imaging  
385 or protein biomarker changes associated with ALS and/or FTD (**Figure 7A**). We identified 231  
386 *FBXO16* PTV carriers ( $n=231$ ), and observed increased risk associated with behavioral and  
387 emotional states in these individuals (R45 category: \*Bonferroni corrected- $p < 0.05$ ) (**Figure**  
388 **7B**). The R45 subcategory of symptoms reported in the UK-Biobank dataset includes apathy,  
389 social isolation and irritability, and we observed that *FBXO16* PTV carriers showed increased  
390 risk of hostility behaviors (logistic regression: \*Bonferroni corrected- $p < 0.05$ ), irritability  
391 (logistic regression: \*Bonferroni corrected- $p < 0.05$ ) and nervousness (logistic regression:  
392 \*Bonferroni corrected- $p < 0.05$ ). Moreover, we also observed a suggestive association with

393 apathic behavior (logistic regression:  $p=0.018$ ) (**Figure 7B**). These results suggest that  
394 carrying a *FBXO16* PTV variant leads to behavioral abnormalities generally associated with  
395 ALS-bi.

396 Next, we sought to test whether *FBXO16* PTV carriers could show altered brain connectivity  
397 and structure, and used the diffusion MRI and T1 structural MRI datasets (Littlejohns et al.,  
398 2020; Miller et al., 2016). Using image-derived phenotypes (IDPs) from diffusion MRI, we  
399 performed an unbiased association analysis to test whether *FBXO16* PTV carriers show  
400 altered white matter structure evidenced by a decrease in fractional anisotropy (FA) or axial  
401 diffusivity. Indeed, *FBXO16* PTV carriers ( $n=13$ ) showed a large decrease in FA in the genu of  
402 corpus callosum (GLM regression:  $FDR<0.05$ ) and decreased axial diffusivity in the left  
403 uncinate fasciculus (GLM regression:  $FDR<0.05$ ) when compared to non-carriers individuals  
404 ( $n=37,817$ ) (**Figure 7C**). Interestingly, previous studies showed a loss of white matter in the  
405 genu of the corpus callosum in patients diagnosed with behavioral variant FTD (Elahi et al.,  
406 2017; Mahoney et al., 2015) and decreased FA in the left uncinate fasciculus in patient  
407 diagnosed with behavioral variant FTD (Mahoney et al., 2015) that correlate with symptoms  
408 severity (D'Anna et al., 2016). Using a whole-brain connectomics analysis and focusing on the  
409 left uncinate fasciculus, we observed that *FBXO16* PTV carriers display a lower number of  
410 white matter tracts (unpaired t-test;  $*p<0.05$ ) connected to distinct frontal region such as the  
411 pars orbitalis (BA47), the pars triangularis (BA45) and the rostral medial frontal cortex (BA46)  
412 (\*Fisher's exact test;  $*p<0.05$ ) (**Figure 7D-F**), that are all parts of the inferior frontal gyrus  
413 (Broca's area) with crucial role in semantic tasks and working memory (Munoz-Neira et al.,  
414 2019). As *FBXO16* PTV carriers showed strong alteration in white matter integrity in a specific  
415 region of the left frontal cortex, we studied possible grey matter changes and analyzed T1-MRI  
416 scans from *FBXO16* PTV carriers and non-carriers. We observed that *FBXO16* PTV carriers  
417 showed a strong decrease in area and volume of the left frontal regions that correspond to the  
418 pars triangularis (BA45) (Cluster-correlation;  $FDR<0.05$ ) (**Figure 7D-F**). Region-specific ROI  
419 analysis indicated a significant decrease of the area (unpaired-t-test;  $**p<0.01$ ) and volume  
420 (unpaired-t-test;  $*p<0.05$ ) in the left pars triangularis (BA45) region in *FBXO16* PTV carriers  
421 while no differences were observed in the right hemisphere (**Figure 7G**). Finally, we studied  
422 whether *FBXO16* PTV carriers show altered plasma protein biomarkers associated with  
423 neurodegenerative diseases. Using the prospective UK-Biobank Olink-based proteomic cohort  
424 (Sun et al., 2023), we selected individuals with incident neurodegenerative disorders including  
425 ALS and dementia. After quality control and inclusion of age and sex-matched individuals  
426 across diseases, we included 24,557 adults without ALS or dementia in the UK Biobank, along  
427 with 1,073 incident cases and a follow-up time of 8.6 years. During this follow-up, 884 (3.7%)  
428 incident dementia cases were identified, of which 118 occurred within 5 years, 350 within  
429 10 years and 415 beyond 10 years. In this population, we observed increased plasma  
430 neurofilament light chain (NEFL) ( $GLM p = 1.96 \cdot 10^{-06}$ ) and glial fibrillary acidic protein (GFAP)  
431 proteins ( $GLM p = 1.96 \cdot 10^{-06}$ ) in FTD (**Figure 7H**). These two proteins were also altered in  
432 different dementia subtypes, including Alzheimer's disease (Bonferroni corrected  $p < 0.05$ ) and  
433 vascular dementia (Bonferroni corrected  $p < 0.05$ ) (**Figure 7H**). In this population, there were  
434 also 223 patients diagnosed with ALS, of which 108 occurred within 5 years, 93 had incidents  
435 within 10 years and 22 had incidents over 10 years. Interestingly, plasma GFAP expression  
436 was unchanged in pure ALS ( $GLM p > 0.05$ ) while NEFL was significantly increased  
437 (Bonferroni corrected  $p < 0.05$ ) in incident dementia, in line with previous studies (Guo et al.,  
438 2024; Katisko et al., 2021). Interestingly, *FBXO16* PTV carriers showed significantly elevated  
439 levels of GFAP protein (permuted- $p < 0.05$ ) as well as NEFL (permuted- $p < 0.01$ ) (**Figure 7H**).  
440 Altogether, our results show that loss of *FBXO16* is associated with behavioral, neuroimaging  
441 and plasma biomarker evidence of altered fronto-temporal network, consistent with prodromal  
442 ALS/FTD.

443

## 444 Discussion

445  
446 Neurodegenerative diseases are defined by three major characteristics: a core set of  
447 symptoms (progressive paralysis for ALS), loss of specific neuronal populations and a typical  
448 proteinopathy (TDP-43 for ALS). However, the clinical picture associated with a specific  
449 neurodegenerative disease can include additional symptoms in some patients. In ALS, for  
450 instance, a substantial fraction of patients develops cognitive impairments. In these ALS-ci  
451 patients, the relation between cognitive impairment and TDP-43 pathology is unclear (Bampton  
452 et al., 2024; Rifai et al., 2024; Suzuki et al., 2024). In most neurodegenerative diseases,  
453 proteinopathies are frequently mixed, and the occurrence of multiple pathologies is generally  
454 related to more severe cognitive impairment. However, the contribution of individual  
455 pathologies to the heterogeneity of symptoms is unclear (Forrest and Kovacs, 2024;  
456 Maldonado-Diaz et al., 2024). Furthermore, in ALS and FTD, FUS proteinopathy is generally  
457 overlooked as it may involve cytoplasmic mislocalization rather than aggregation (Rifai et al.,  
458 2022; Tyzack et al., 2019).

459 A first important result of this study is that FUS mislocalization in CPNs drives ALS-ci/bi-like  
460 impairments in ALS. This result is substantiated by correlative evidence in patients as FUS  
461 mislocalization in CPNs is observed in ALS-ci patients, but not in those without cognitive  
462 impairments. Consistently, the typical signature of FUS-related dysfunction was observed in  
463 L5-ET neurons of ALS-ci patients and related to cognitive impairment at the individual patient  
464 level. Whilst the absence or presence of TDP-43 pathology is associated with the absence or  
465 presence of cognitive dysfunction (Gregory et al., 2020), no protein misfolding pathology has  
466 previously been shown to correlate with the burden of symptoms, highlighting the importance  
467 of this finding with respect to FUS. Beyond correlative evidence, we provide functional, *in vivo*,  
468 evidence that mislocalization of FUS in adult CPNs is sufficient to drive cognitive and  
469 behavioral impairment in a novel mouse model. These behavioral abnormalities were observed  
470 a few weeks after the induction of FUS mislocalization and phenocopied cognitive and  
471 behavioral impairments in ALS-ci/bi patients. Contrastingly, these mice were spared of motor  
472 defects even after more than one year of follow up. This finding indicates that the occurrence  
473 of FUS mislocalization in CPNs might drive cognitive impairment in ALS patients already  
474 presenting the motor symptoms. Our current results suggest that FUS mislocalization should  
475 be systematically included in the pathological characterization of ALS-ci/bi patients, and,  
476 beyond in neurodegenerative diseases with cognitive and behavioral impairments.

477 How could FUS mislocalization be triggered in CPNs of ALS-ci/bi patients? In rare cases, ALS  
478 patients carry germline mutations of *FUS* that increase FUS mislocalization (Kwiatkowski et al.,  
479 2009; Vance et al., 2009). These mutations generally lead to severe motor phenotypes and  
480 there are few studies characterizing possible cognitive impairments in these *FUS*-ALS  
481 patients. However, learning disabilities and mental retardation have been observed in *FUS*-  
482 ALS patients especially in severely affected patients (Goldstein et al., 2022; Grassano et al.,  
483 2022; Hirayanagi et al., 2016; Lanteri et al., 2021). There are also reports of patients with *FUS*  
484 variants showing fronto-temporal dementia phenotype either isolated or with an initial  
485 presentation of ALS-FTD (Aguzzoli et al., 2022; Broustal et al., 2010; Van Langenhove et al.,  
486 2010). However, most ALS-ci patients do not present a germline *FUS* mutation, and FUS  
487 mislocalization is likely, in these cases, secondary to other pathogenic events. In cell models,  
488 FUS mislocalization can be elicited by various stresses including arsenite (Bosco et al., 2010;  
489 Dormann et al., 2010; Szewczyk et al., 2023), osmotic stress (Gao et al., 2022; Hock et al.,  
490 2018), antiviral response (Bellmann et al., 2019; Shelkovnikova et al., 2019) or nuclear pore  
491 defects (Lin et al., 2021), suggesting the contribution of environmental insults to FUS  
492 mislocalization. In addition, pathological mislocalization of FUS could also result from  
493 aggregation of other RNA-binding proteins, such as TAF-15 (Tetter et al., 2024) in FTLD-FET,

494 or from pathological spreading of FUS from neighboring cells (Vazquez-Sanchez et al., 2024).  
495 Last, FUS mislocalisation could also result from increased genetic burden that ultimately drives  
496 this pathological hallmark in vulnerable neurons. The latter mechanism is supported by our  
497 observation of increased dementia-related genetic burden in ALSci patients that correlates  
498 with the extent of FUS regulon downregulation. It is however very likely that a conjunction of  
499 these different mechanisms leads to FUS mislocalisation and downregulation of the FUS  
500 regulon in vulnerable L5-ET neurons. Whatever the underlying cause of FUS mislocalization,  
501 our study demonstrates that its induction in adult CPNs is on its own sufficient to lead to ALS-  
502 ci relevant cognitive symptoms.

503 A second major result of our study is that FUS mislocalization drives genetic risk of cognitive  
504 and behavioral impairment in ALS. A previous survey of relationships between RBPs binding  
505 targets and ALS heritability showed that target binding sites of 6 RBPs, including TDP-43 and  
506 FUS, were associated with ALS risk (Megat et al., 2023). This finding is consistent with the  
507 major GWAS hit *UNC13A* being a TDP-43 target (Brown et al., 2022; Ma et al., 2022). However,  
508 gene targets of TDP-43 or FUS are cell-type dependent (Jeong et al., 2017), and it was critical  
509 to identify those in CPNs. Here we identify a set of genes regulated by FUS mislocalization in  
510 CPNs through a cross-species approach. This cross-species approach increases the  
511 robustness of target identification by conserving them across species and cell types, but is  
512 conservative. We cannot exclude that additional, human-specific FUS-regulated genes could  
513 be missing from the current FUS-regulon gene list. It is unlikely that all these FUS-regulated  
514 genes share a unique FUS-dependent regulatory mechanism as FUS is a multi-functional  
515 RNA-binding protein, involved at all steps of gene expression, from transcription to splicing,  
516 local translation or microRNA-mediated regulation (Lagier-Tourenne et al., 2010; Picchiarelli  
517 et al., 2019; Piol et al., 2023). It is also possible that some of these FUS regulon genes are  
518 indirect FUS targets and the precise mechanisms linking these genes to FUS will have to be  
519 determined on a gene-by-gene basis in further studies. Importantly, TDP-43 also regulates  
520 RNA levels of FUS-regulon genes suggesting that convergent loss of function of FUS and  
521 TDP-43 could synergize in leading to ALS neurotoxicity (Lagier-Tourenne et al., 2012).

522 ALS-linked genes were significantly enriched in the FUS regulon, and a substantial number of  
523 ALS genes were present in this regulon, including familial genes (*C9ORF72*, *KIF5A*, *ERBB4*,  
524 *FUS* itself), but also genes with common ALS-associated variants such as *NEK1*, *SCFD1* or  
525 *SARM1*. Interestingly, genes of the FUS regulon are associated with ALS with  
526 cognitive/behavioral impairment including *C9ORF72* (Diekstra et al., 2014), *KIF5A* (Dulski et  
527 al., 2023; Saez-Atienzar et al., 2020), *FUS* (Aguzzoli et al., 2022; Broustal et al., 2010; Van  
528 Langenhove et al., 2010), *ERBB4* (Sun et al., 2020), or *SCFD1* (Chen et al., 2024). This finding  
529 suggests that the genes of the FUS regulon could be enriched in genes relevant for ALS-ci  
530 and ALS-bi rather than pure ALS. Consistently, we were able to uncover robust genetic  
531 associations between common variants in *FBXO16* and *WWOX* with ALS-bi and ALS-ci  
532 respectively. *WWOX* has been genetically associated with Alzheimer's disease (Kunkle et al.,  
533 2019) and to risk of cognitive progression in Parkinson's disease (Liu et al., 2021), and  
534 dementia in limbic-predominant age-related TDP-43 encephalopathy neuropathological  
535 change (LATE-NC), hippocampal sclerosis, and brain arteriolosclerosis (Dugan et al., 2022)  
536 indicating that this gene is broadly associated to cognitive deficits in multiple  
537 neurodegenerative diseases. *WWOX* encodes for a protein of poorly characterized function  
538 that has been suggested to indirectly modulate transcriptional activity and cell proliferation  
539 (Kosla et al., 2019). Its function in neurons is poorly documented, but it is worth noting that  
540 loss-of-function mutations are also associated with *WWOX*-related epileptic encephalopathy  
541 (WOREE) syndrome characterized by intractable epilepsy, severe developmental delay, motor  
542 deficits and premature death at the age of 2-4 years (Mallaret et al., 2014). Consistently,  
543 ubiquitous or neuronal deletion of *Wwox* in mice leads to a complex neurodevelopmental and

544 neurodegenerative phenotype (Cheng et al., 2020; Repudi et al., 2021). Our results suggest  
545 that mild loss of *WWOX* could sensitize to cognitive impairment during ALS, thereby favoring  
546 an ALS-ci clinical picture.

547 We also show a genetic association between *FBXO16* and ALS-bi, and loss of *FBXO16* in  
548 PTV carriers is sufficient to lead to multiple abnormalities in behavior, neuroanatomy and  
549 circulating biomarkers all consistent with fronto-temporal damage. *FBXO16* encodes for a  
550 largely uncharacterized F-box containing protein. F-box containing proteins are well known for  
551 their E3 ubiquitination ligase function in the SCF complex (SKP1-CULLIN1-F-box protein) and  
552 it is thus likely that *FBXO16* is important in the ubiquitination and possibly degradation of  
553 specific, currently unknown, substrates(Wang et al., 2014). In cancer cells, *FBXO16* has been  
554 shown to inhibit the beta-catenin pathway through proteosomal targeting of nuclear beta-  
555 catenin (Khan et al., 2019; Paul et al., 2019). Whether this function is related to behavioral  
556 impairment in *FBXO16* PTV carriers or in ALS-bi patients carrying *FBXO16* common variant  
557 remains to be determined. Nonetheless, our newly defined association between *FBXO16* and  
558 ALS-bi, indicates that perturbations in proteostasis likely contribute to disease pathogenesis.

559 In totality, our study demonstrates that additional FUS pathology is a contributor to cognitive  
560 impairment occurring in ALS patients and is related to the genetic risk of ALS-related cognitive  
561 and behavioral impairments. We further identify and replicate *FBXO16* as a novel gene  
562 contributing to behavioral impairments in ALS.

563  
564

## 565 **Methods**

566

### 567 **Patients tissue staining**

#### 568 Ethics:

569 All clinical data including the ECAS were collected as part of Scottish Motor Neuron Disease  
570 Register (SMNDR) and Care Audit Research and Evaluation for Motor Neuron Disease  
571 (CARE-MND) platform (ethics approval from Scotland A Research Ethics Committee  
572 10/MRE00/78 and 15/SS/0216) and all patients consented to the use of their data during life.  
573 All post-mortem tissues were collected via the Edinburgh Brain Bank (ethics approval from  
574 East of Scotland Research Ethics Service, 16/ES/0084) in line with the Human Tissue  
575 (Scotland) Act. Use of human tissue for post-mortem studies has been reviewed and approved  
576 by the Edinburgh Brain Bank ethics committee and the Academic and Clinical Central Office  
577 for Research and Development (ACCORD) medical research ethics committee (AMREC).  
578 BA39 was selected as a brain region that assesses language function and had been evaluated  
579 in at least 6 *C9ORF72* patients with 3 demonstrating impairment (as measured by clinically  
580 approved cut-offs measured by the Edinburgh Cognitive ALS Screening tool (Gregory et al.,  
581 2020). BA4 was used as a representative region of the motor cortex.

582

#### 583 Immunohistochemical staining:

584 Immunohistochemistry was performed on 4  $\mu$ m-thick sections on superfrost charged slides.  
585 Sections were deparaffinized, followed by antigen retrieval using citric acid pH6. Sections were  
586 then stained using the Novolink Polymer detection system (DAB chromogenic staining) using  
587 FUS primary antibody (BioTechne NB100-595) at 1 in 500 dilution. Counterstaining was  
588 performed using lithium carbonate and haematoxylin. Slides were imaged using an EVOS  
589 M5000 microscope using brightfield settings at 10x and 40x magnification.

590

### 591 **Mouse breeding and genotyping**

592 Mice were housed in our animal facility (Strasbourg), with a regular 12h light and dark cycle  
593 under constant conditions ( $21 \pm 1^\circ\text{C}$ , 60% humidity) and unrestricted access to food and water.  
594 Double transgenic mice were generated by crossing Thy1.2 CreERT2 mice (The Jackson  
595 Laboratory, JAX stock #012708 STOCK Tg(Thy1-cre/ERT2,-EYFP)HGfng/PyngJ) (Caroni,  
596 1997; Feil et al., 1997; Young et al., 2008) with mice carrying the nuclear localization signal  
597 (NLS) of *Fus* flanked by two LoxP sequences (Mouse Clinical Institute of Strasbourg,  
598 Phenomin-ICS). We obtained offspring in which a tamoxifen-inducible Cre-mediated  
599 recombination aimed at deleting the NLS of FUS specifically in long projection neurons. We  
600 used mice containing two alleles with a LoxP-flanked *Fus* NLS sequence (*FusLoxP/LoxP*,  
601 referred to as "*Fus<sup>exon15</sup>*") and homozygous double mutant mice (Thy1.2 CreERT2  
602 *FusLoxP/LoxP*, referred to as "*Thy1-Fus<sup>exon15</sup>* mice"). Mice were carefully handled to reduce  
603 their stress and anxiety. Experimental protocols and animal care complied with the institutional  
604 guidelines (council directive 87/848, 19 October 1987, Ministry of Agriculture and Forestry,  
605 Veterinary Department of Health and Animal Protection) and international laws (directive  
606 2010/63/UE609, 13 February 2013, European Community) and policies (personal  
607 authorization #I-67UnivLouis Pasteur-F1-04 for R.C.). The project has been approved by the  
608 ethics committee of Strasbourg (CREMEAS, reference number: FUS NLS inducible\_#12173-  
609 2018062510569395).

610

### 611 **Primary neuronal cultures**

612 Primary cortical cells were taken from homozygous *Fus<sup>exon15</sup>* E145 mouse embryos and  
613 cultured in complete neurobasal medium, i.e. Neurobasal medium (ThermoFisher)  
614 supplemented with 1% Penicillin/Streptomycin (Sigma), 1% GlutaMAX (ThermoFisher) and 2%  
615 B27 (ThermoFisher). Dissected cortices were incubated with trypsin/EDTA (Sigma) and  
616 DNase (50U/ml final\_Sigma), washed, and triturated to give a single cell suspension. Cells

617 were cultured for 3-4 h in complex neurobasal medium complemented with 10% FBS  
618 (Thermofisher). From day 1 to day 14, we used complete neurobasal medium and changed  
619 the medium every 2-3 days. Cultured neurons were then exposed to an adenoviral vector (Ad-  
620 CRE-GFP, Vector biolab, #1700 and ad-CMV-GFP, Vector biolab, #1060 as control) at MOI 1,  
621 10, and 100 either 5 or 14 days after plating.  
622

### 623 **Induction of recombination in adult mice**

624 The recombination was induced at 1.5-months of age by forced-feeding mice of both  
625 genotypes (*Fus<sup>exon15</sup>* and *Thy1-Fus<sup>exon15</sup>* mice) with 100  $\mu$ L of tamoxifen at 20 mg/mL (Sigma)  
626 diluted in Corn oil (Sigma) for 5 consecutive days. We waited another month and a half before  
627 doing the different procedures (i.e. behavioral studies or dissection for biochemical analyses).  
628

### 629 **Behavioral studies in mice**

630 All behavioral studies were made in the morning during the light phase and the experimental  
631 procedure started after a 30-minute period of habituation to the experimental room. Mice were  
632 handled for at least five days to reduce stress and anxiety due to manipulation.  
633

#### 634 Motor test

635 Mice were subjected to the inverted grid test to noninvasively assess the ability of mice to use  
636 sustained limb tension to oppose their gravitational force (Carlson et al., 2010). Each mouse  
637 was placed on a grid and was allowed to adapt to this environment for 15-20 s. The grid was  
638 then inverted and held approximately 35 cm over a cage containing 5 cm of wood chips. We  
639 assessed the hanging time, i.e. the time the mice hold before falling, for three trials with 5-  
640 minute breaks between each and a cut-off time of 5 min. The mouse body mass was measured  
641 shortly before the test to compute the minimal total sustained force that was exerted to oppose  
642 the gravitational force: holding impulse (N.s) = averaged hanging time (s)  $\times$  body mass (g)  $\times$   
643 0.00980665 (N.g<sup>-1</sup>).  
644

#### 645 Nest building test

646 Nesting abilities were measured based on a previously described protocol (Deacon, 2006). One  
647 hour before the dark phase, enrichment items were removed from individual home cages and  
648 3 g of pressed cotton pieces (i.e. approximately 6 pieces) were given to each mouse. After 24h  
649 nests were assessed with the five-point scale used by Deacon (Deacon, 2006). Untorn cotton  
650 pieces were counted and weighed.  
651

#### 652 Three-chamber social task

653 The experimental procedure was adapted from Gascon E et al (Gascon et al., 2014). The three-  
654 chamber box (59  $\times$  39.5  $\times$  21.5 cm) is made of transparent Plexiglas (Noldus Information  
655 Technology, Wageningen, The Netherlands) and is divided into three chambers (one middle  
656 and two side chambers) of equal size (18.5  $\times$  39.5 cm) by the walls with a square opening (7  
657  $\times$  7 cm) that could be closed by a slide door. Each tested mouse was placed in the middle of  
658 the central compartment that was kept empty while the two others compartments contained an  
659 openwork cylindrical cage (20  $\times$  10 cm diameter made of transparent Plexiglas bars). After the  
660 habituation session (one trial with free access of the arena containing two empty cages), mice  
661 were placed three times (15-minute inter-trial interval) in the arena containing a cage with a  
662 mouse (referred to as "mouse") and an empty cage. Mice were placed one last time in the  
663 arena containing a cage with the known mouse (i.e. the mouse already meet tree times during  
664 the previous phase) and a cage with a novel mouse (referred to as "Novel mouse"). For all  
665 sessions, mice were free to explore the arena for 5 min while being recorded. For all sessions,  
666 mice were free to explore the arena for 5 min while being recorded. Two parameters were  
667 measured using the EthoVision XT software (Noldus Information Technology) : total distance  
668 travelled and velocity. The time spent contacting the empty cage and the strangers was

669 measured by hand. The recognition index (RI) was calculated according to this formula:  $RI =$   
670 contact time with stranger 2 / total contact time  $\times 100$ .

671

#### 672 Resident-intruder social task (social interaction in home cage)

673 Briefly, after 30 minutes of habituation to the test room resident mouse was allowed to freely  
674 roam in its home cage without the cage top for 1 min. A novel male intruder mouse (non-  
675 littermate of the same background, same age, and similar weight) was introduced in the  
676 opposite corner as the resident. We recorded the interaction for 5 min to assess social  
677 activities: total physical interaction (active exploration of the intruder) comprising investigating,  
678 grooming, following and sniffing(Scekic-Zahirovic et al., 2021).

679

#### 680 Dark/light box test:

681 The apparatus consisted of a polypropylene cage (44  $\times$  21  $\times$  21 cm) separated into two  
682 compartments with a small opening (12  $\times$  5 cm) at floor level. The first compartment (28 cm  
683 long) was open-topped, transparent, and brightly illuminated by white light from a 40-watt desk  
684 lamp positioned above the lit chamber (140 lux). The second compartment is smaller (14 cm  
685 long) and covered at the top with black Plexiglas and painted black on all sides. Mice were  
686 individually placed in the center of the dark compartment and allowed to freely explore the  
687 apparatus for 5 min. The apparatus was cleaned with a 30% ethanol solution between  
688 subjects. We assessed the number of light/dark transitions between the two compartments,  
689 the latency to first get out of the dark box, and the total time spent in the light compartment.

690

#### 691 Object recognition test:

692 The novel object recognition test was performed to investigate learning and memory in  
693 mice(Lueptow, 2017). Each mouse was placed in the middle of an open and squared arena  
694 containing two objects. The position of these objects was the same for all sessions and the  
695 objects and arena were cleaned with 70% (v/v) ethanol. For the habituation (day 1), mice were  
696 placed two times, with a 10-minute break in between, in the arena containing two identical  
697 objects (empty tips boxes). Object recognition was tested after a short retention time (10 min)  
698 to evaluate short-term memory (day 2) and after a longer one (24h) to look at long-term  
699 memory (days 3 and 4). Mice were first placed in the arena with two identical objects (either  
700 two water glasses for short term memory or two glass bottles for long-term memory). Then, for  
701 memory assessment, one of the previous objects was replaced by a novel one (a 15-cm high  
702 vial for short-term memory and stemmed glass for long term memory). For all sessions mice  
703 were free to explore the arena during 10 min while being recorded. Two parameters were  
704 measured using the EthoVision XT software (Noldus Information Technology): total distance  
705 travelled and velocity. The times spent exploring the identical objects, the known object (Tk)  
706 or the novel one (Tn) were manually determined. The recognition index (RI) was calculated  
707 according to this formula:  $RI = \text{exploration time of the novel object (Tn)} / \text{total exploration time}$   
708  $(Tk + Tn) \times 100$ .

709

#### 710 Sucrose splash test:

711 The protocol, adapted from Isingrini et al. (2010),(Isingrini et al., 2010) consists of spraying a  
712 10% sucrose solution on the dorsal coat of a mouse in its home cage. Due to sucrose's  
713 viscosity, the sucrose solution dirties the mouse fur and animals initiate grooming behaviors.  
714 Once the sucrose solution was applied, latency (time between spray and initiation of grooming)  
715 and duration of grooming were recorded for 5 minutes.

716

#### 717 Sucrose preference test:

718 The Sucrose Preference Test (SPT) is a reward-based test used as an indicator of anhedonia.  
719 We used a protocol adapted from Serchov et al.(Serchov et al., 2016). Briefly, mice were  
720 presented for three days in their home cage with two identical-looking bottles, but one contains  
721 water while the other contains a sucrose solution (1%, EMD Millipore, catalog number:

722 573113). Consumption of water and sucrose solution was measured daily, and the positions  
723 of the two bottles were interchanged each day to reduce any risk of lateral bias. Sucrose  
724 preference (SP) was calculated as a percentage of the volume of sucrose intake over the total  
725 volume of fluid intake and averaged over the three days of testing according to this formula:  
726  $SP = V(\text{sucrose solution})/[V(\text{sucrose solution})+V(\text{water})] \times 100\%$ .

727

## 728 **Electrocorticography in mice**

### 729 Surgery:

730 Surgery procedures were similar to previous studies(Guillot et al., 2025; Scekcic-Zahirovic et  
731 al., 2024). Briefly, mice were deeply anaesthetized using 4% isoflurane (Baxter). Prior to the  
732 procedure, injectable meloxicam (Metacam, 10mg/mL, Boehringer Ingelheim) was provided  
733 subcutaneously to the animals. After local subcutaneous injection of lidocaine (Lurocaine,  
734 2mg/kg, Vetoquinol), animals were stereotaxically implanted with electrodes at the following  
735 coordinates: Reference electrode: Bregma +0.50mm, midline +0.00mm; Ground electrode:  
736 Bregma -3.00mm, midline -3.00mm; Recording electrode 1: Bregma +2.50mm, midline  
737 +2.00mm; Recording electrode 2: Bregma -2.50mm, midline -2.00mm. The incision was closed  
738 using dental cement (Super-Bond C&B). The animals were returned to their home cage and  
739 given meloxicam (Metacam, 5mg/mL, Boehringer Ingelheim) *ad libitum* in their drinking water  
740 for five days after the procedure.

741

### 742 Analysis:

743 Electrocorticography (ECoG) recordings were conducted on Thy1<sup>CRE-ERT2</sup>/*Fus*<sup>exon15</sup> mice and  
744 their respective control littermates at 3 and 5 months of age, over a 24-hour period. ECoG was  
745 recorded using LabChart (LabChart version 5, ADInstruments, USA). ECoG signals were  
746 collected with a 2,000Hz sampling rate. The Python package EEVop(Guillot, 2023) was used  
747 to analyze the ECoG traces. To remove the powerline (50Hz) and its harmonics up to 200Hz,  
748 ECoGs were notch-filtered. A Z-score was used to normalize each ECoG recording. The Z-  
749 score of each recording was compared with the mean Z-score of the control animals. Only  
750 events that exceeded the baseline Z-score were counted. To ensure proper removal of  
751 background noise, a window discriminator of four times the baseline standard deviation was  
752 used for event detection.

753

## 754 **Immunostaining in mice and imaging**

755 Immunolabelling experiments were performed 1.5 months after tamoxifen administration. The  
756 mice were deeply anaesthetized using an intraperitoneal injection of pentobarbital (60 mg/kg)  
757 and then transcardially perfused with cold 4% PFA in 0.01 M phosphate-buffered saline (PBS).  
758 After dissection (brain and spinal were splitted), brains were post-fixed for 24 hours and then  
759 included in agar 4% and serial cuts of 40  $\mu\text{m}$  thick were made using vibratome (Leica  
760 Biosystems, S2000). After three washes (0.1M PBS), tissues were incubated for a 30 min  
761 period in citrate sodium buffer (pH 6, 10 mM) at 85°C and then left for 90 min in PBS with 0,5%  
762 Triton X-100 and 5% donkey serum under slow agitation. The primary antibodies were  
763 incubated in 0.1% Triton X-100 and 1% donkey serum in PBS for 24h at 4°C: rabbit@FUS N-  
764 ter (Protein Tech, #11570-1-P, 1/250), rabbit@FUS C-ter (Bethyl, #A300-294, 1/500),  
765 chicken@GFP (Abcam, #a13970, 1/1000), goat@ChAT (Millipore, #AB114P, 1/1000),  
766 mouse@NeuN (Millipore, #MAB377; 1/250), goat@Iba1 (abcam, #ab5076, 1/250),  
767 rabbit@GFAP (Dakocytomation, 1/250). After three washes, the secondary antibodies were  
768 incubated in 0.1% Triton X-100 in PBS overnight at 4°C: Alexa Fluor 488 donkey anti-chicken  
769 IgG H&L (JacksonLab, #703-545-155 5, 1/500); Alexa Fluor 647 donkey anti-rabbit IgG H&L  
770 (JacksonLab, #711-605-152, 1/500); Alexa Fluor 555 donkey anti-mouse IgG H&L (Molecular  
771 Probe, #A21203, 1/500), Alexa Fluor 555 donkey anti-goat IgG H&L (JacksonLab, #705-605-  
772 147, 1/500). A chromatin staining with DAPI was performed between the two final washes. The  
773 sections were oriented and mounted in Mowiol 4-88 medium (Sigma).

774 Image acquisition was performed at the Imaging Core Facility of Strasbourg Biomedical  
775 Research Centre (University of Strasbourg, INSERM, PIC-STRA, UMS 38). Fluorescence  
776 images were acquired using a Zeiss (LSM 710 NLO) confocal microscope with a 20x Zeiss  
777 Plan Apochromat oil-immersion lens (NA 1.40) controlled with the Zen software (ZEN 2012  
778 Black edition, Carl Zeiss Microscopy GmbH, Germany). Images were acquired to a resolution  
779 of 2048x2048 pixels at subsaturating laser intensities for each channel. To evaluate the  
780 percentage of recombined neurons (in the brain) and motoneurons (in the spinal cord), we  
781 performed manual counting with FIJI free software(Schindelin et al., 2012). The measurement  
782 of the number of neurons in the frontal and motor cortex was made using a homemade macro.  
783

## 784 **Western blotting and subcellular fractionation**

### 785 Subcellular fractionation and Western Blotting

786 Tissues were washed in 1x PBS and lysed in NE-PER Nuclear and Cytoplasmic Extraction  
787 (Thermo Scientific, 78835) according to the manufacturer's instructions. Protein extracts were  
788 dosed by BCA Assay (Interchim, UP95424A). Proteins were denatured and SDS page was  
789 performed with 30 µg of cytoplasmic proteins and 10 µg of nuclear proteins on Criterion TGX  
790 stain-free gel 4–20 % (Biorad, 5678094). Proteins were blotted on nitrocellulose membrane  
791 using semi-dry Transblot Turbo system (BioRad, France) and blocked with 10 % non-fat milk  
792 during 1 h. Primary antibodies (Rabbit anti-FUS C-ter targeting the NLS (Bethyl, #A300-294 A,  
793 1/2000), Rabbit anti-FUS N-Ter (Bethyl, #A-300-293 A, 1/2000), Sheep anti-SOD1  
794 (Calbiochem, 574597, 1/1000), Rabbit anti-HDAC1 (Bethyl, #A300-713 A, 1/1000) were  
795 incubated overnight at 4 °C in 3 % non-fat milk. Washing was proceeded with washing buffer  
796 (Tris pH 7.4 1 M, NaCl 5 M, Tween 20 100 %) and secondary antibodies (anti-rabbit HRP  
797 (PARIS, #BI2407,1/5000), anti-sheep HRP (Jackson, #713-035-147, 1/5000); anti-Rat HRP  
798 (Rockland, 612-1102, 1/5000) were incubated for 1h30 at room temperature. After successive  
799 washes, proteins were visualized with chemiluminescence using ECL Lumina Forte (Millipore,  
800 France) and chemiluminescence detector (Bio-Rad, France). Total proteins were detected with  
801 stain-free gel capacity (Biorad, 5678094) and used to normalize for protein loading.  
802

## 803 **RT-qPCR**

### 804 Genomic DNA isolation and PCR

805 Genomic DNA was extracted from hippocampi and lumbar spinal cord using KTT Buffer (Tris  
806 HCl, Triton and KCL) with Proteinase K (Sigma, 20mg/mg). DNA was purified using  
807 Phenol/Chloroforme (Sigma, P2069) and washed with 70% Ethanol. Polymerase chain  
808 reaction (PCR) was performed with MasterMix Taq DNA polymerase (VWR International, Ref.  
809 733–1320) and the following primers : LF2 : 5'- CTA-GCC-CAC-CTC-CTA-ATC-CTC-ATC-  
810 AC-3' ; LR2 : 5'- CCA-CAC-TTT-AGG-TTA-GTC-ACA-GAT-CAG-C-3' and LXR : 5'- GGA-  
811 TCC-GCG-GGA-AGT-TCC-TAT-AC-3'. PCR1 correspond to LF2 + LR2 and PCR2 correspond  
812 to LF2 + LXR. The following program was used : 5 min 95°C ; (30 s 95°C ; 30 s 62°C ; 30 s  
813 72°C) x 34 ; 5 min 72°C). 10 µL of the PCR products were loaded on a 2 % agarose  
814 (Euromedex, Ref.D5-E) gel electrophoresis with Low Molecular Weight DNA Ladder (NEB,  
815 Ref. N3233L) and stained with ethidium bromide using standard procedures.  
816

### 817 RNA extraction and quantitative PCR

818 Total RNA was extracted from hippocampi and lumbar spinal cord using TRIzol® reagent (Life  
819 Technologies). 1 µg of RNA was reverse transcribed with iScript™ reverse transcription  
820 (Biorad, 1,708,841). Quantitative PCR was performed using Sso Advanced Universal SYBR  
821 Green Supermix (Bio-Rad 1,725,274) and quantified with Bio-Rad software. Gene expression  
822 was normalized by calculating a normalization factor using actin, TBP and pol2 genes  
823 according to GeNorm software. Primer sequences are provided in Table XX.  
824

## 825 RT-PCR

826 1 µg of RNA was reverse transcribed with iScript™ reverse transcription (Biorad, 1,708,841).  
827 PCR was performed using in 25 µL microtubes with MasterMix Taq DNA polymerase (VWR  
828 International, Ref. 733–1320) and the following programs: Intron 6 retention (5 min 95 °C, (30  
829 s 95 °C, 30 s 56 °C, 30 s 68 °C) x 30; 5 min 68 °C), Intron 7 retention (5 min 95 °C, (30 s 95  
830 °C, 30 s 61 °C, 30 s 68 °C) x 30; 5 min 68 °C), 10 µL of the PCR products were loaded on a 2  
831 % agarose (Euromedex, Ref.D5-E) gel electrophoresis with Low Molecular Weight DNA  
832 Ladder (NEB, Ref. N3233L) and stained with ethidium bromide using standard procedures.  
833 The signal intensity of each of the two bands was quantified individually, and a percentage of  
834 intron retention was computed according to this formula: (intensity of Intron + band) / (intensity  
835 of Intron + band + intensity of Intron - band) × 100.

836

### 837 **Single nuclei RNA sequencing**

#### 838 10x Genomics Chromium single-cell 3' library construction

839 Cell capture, amplification and library construction on the 10x Genomics Chromium platform  
840 were performed according to the manufacturer's publicly available protocol. Briefly, viability  
841 was assessed by trypan blue exclusion assay, and cell density was adjusted to 175 cells per  
842 microliter. In total, 7,000 cells were then loaded onto a single channel of a 10x Chromium chip  
843 for each sample. The 10x Genomics Chromium technology enables 3' digital gene expression  
844 profiling of thousands of cells from a single sample by separately indexing each cell's  
845 transcriptome. Primers containing (i) an Illumina R1 sequence (read 1 sequencing primer), (ii)  
846 a 16-nucleotide 10x Barcode, (iii) a 10-nucleotide UMI, and (iv) a poly-dT primer sequence  
847 were released and mixed with cell lysate and Master Mix. Incubation of the GEMs then  
848 produced barcoded, full-length cDNA from polyadenylated mRNA. After incubation, the GEMs  
849 were broken and the pooled fractions were recovered. Full-length, barcoded cDNA was then  
850 amplified by PCR to generate sufficient mass for library construction. Enzymatic fragmentation  
851 and size selection were used to optimize the cDNA amplicon size before library construction.  
852 R1 (read 1 primer sequence) was added to the molecules during GEM incubation. P5, P7, a  
853 sample index and R2 (read 2 primer sequence) were added during library construction via end  
854 repair, A-tailing, adaptor ligation and PCR. The final libraries contained the P5 and P7 primers  
855 used in Illumina bridge amplification. The described protocol produced Illumina-ready  
856 sequencing libraries. A single-cell 3' library comprises standard Illumina paired-end constructs  
857 that begin and end with P5 and P7. The single-cell 3' 16-bp 10x Barcode and 10-bp UMI are  
858 encoded in read 1, while read 2 is used to sequence the cDNA fragment. Sample index  
859 sequences were incorporated as the i7 index read. Read 1 and read 2 are standard Illumina  
860 sequencing primer sites used in paired-end sequencing. Sequencing the library produced a  
861 standard Illumina BCL data output folder. The BCL data include the paired-end read 1  
862 (containing the 16-bp 10x Barcode and 10-bp UMI) and read 2 as well as the sample index in  
863 the i7 index read.

864

#### 865 Processing of *Fus*<sup>ANLS</sup> mice single-cell RNA-seq data

866 Raw FASTQ files were aligned to the pre-mRNA annotated mouse reference genome  
867 GRCm10. Cell Ranger v.4.0 with default parameters was used to demultiplex and align our  
868 barcoded reads with the Ensembl transcriptome annotation (GRCm10). The majority of our  
869 downstream analysis was conducted using the R programming language (v.4.0.5 for  
870 harmonization and clustering, v.4.1.0 for annotation and downstream visualization) and the  
871 RStudio integrated development environment. A recent report suggested that filtering cells with  
872 greater than 10% mitochondrial reads is the preferred baseline for human tissue, and that for  
873 brain tissue a higher threshold may even be optimal. Thus, a mitochondrial percentage that  
874 was the higher of either 10% of reads or the two absolute deviations above the median for  
875 mitochondrial reads within the sample was chosen as a threshold. Cells below this threshold  
876 with between 500 and 10,000 UMIs were retained for downstream analysis. All ribosomal  
877 genes, mitochondrial genes and pseudogenes were removed, as they interfered with the  
878 downstream differential gene expression.

879

### 880 Processing of ALS patients' single nuclei RNA sequencing.

881 Raw FASTQ files were downloaded from Pineda et al.(Pineda et al., 2024) and aligned to the  
882 pre-mRNA annotated human reference genome GRCh38 using Cell Ranger v4.0 (10x  
883 Genomics, Pleasanton CA). Introns were annotated as 'mRNA', and intronic reads were  
884 included to quantify expression. Quality control criteria were used as previously described  
885 (Bakken et al., 2021) so that for Cv3, criteria were: more than 500 (non-neuronal nuclei) or  
886 more than 1,000 (neuronal nuclei) genes were detected and doublet score was less than 0.3.

887

### 888 Clustering

889 Nuclei were grouped into transcriptomic cell types using an iterative clustering procedure.  
890 Read counts were summed, and  $\log_2$ -transformed expression was centered and scaled across  
891 nuclei. The graph-based clustering approach implemented in Seurat (v.5) was used to cluster  
892 our cells. In brief, a  $k$ -nearest neighbors graph based on Euclidean distance in our corrected  
893 mNN space was calculated and used to derive refined edge weights based on Jaccard  
894 similarity. The Louvain algorithm was then applied to iteratively delineate a population structure  
895 on our dataset. This was implemented with the FindNeighbors and FindClusters functions in  
896 Seurat. A UMAP projection of our dataset was computed with the RunUMAP function for  
897 visualization (Figure 1). Differentially expressed genes (DEGs) for a given cluster were  
898 identified by using Seurat's FindAllMarkers function with a Wilcox test and comparing each  
899 cluster with every other cluster under the same subclass, with logfc.threshold set to 0.25 and  
900 min.pct set to 0.5. The union of up to 50 genes per cluster with the highest average logFC was  
901 used. The average  $\log_2$  expression of the DEGs was then used as input for the build\_dend  
902 function from scratth.hicat to create the dendrograms.

903

### 904 Cell type annotation

905 A curated set of known major cell type markers based on Bakken et al., 2021 was used to  
906 annotate individual cells with their expected cell type and assign a confidence score to each  
907 annotation. For ambiguous subpopulations, we assigned identity based on visually distinct,  
908 well-defined gene expression domains reproducibly identified by Leiden clustering at multiple  
909 resolutions. Descriptive labels were determined by the unique co-expression of marker  
910 genes identified by Seurat for each subclass.

911

### 912 Pseudobulk differential expression analysis

913 Cell type-specific pseudo-bulk differential gene expression (DGE) groups were built based on  
914 hierarchical clustering and Euclidean distance between each cell subclass. The pseudobulk  
915 methods employed the edgeR for analysis of aggregated read counts. Briefly, for cells of a  
916 given type, we first aggregated reads across biological replicates, transforming a genes-by-  
917 cells matrix to a genes-by-replicates matrix using matrix multiplication. For each differential  
918 expression cluster, only genes present in at least 10% of cells were retained for analysis.  
919 Counts were depth normalized, scaled by library-size, and  $\log_2$ -transformed. Pseudo-bulk  
920 expression profiles were computed by averaging normalized log-counts within each cluster for  
921 each unique sample. We used surrogate variable analysis(Leek et al., 2012) (implemented in  
922 the SVA R package) to identify and remove sources of unknown variance. We used the quasi-  
923 likelihood F-test approach (edgeR-QLF) and gene were considered differentially expressed for  
924  $FDR < 0.05$ .

925

### 926 Cross-species consensus co-expression analysis

927 To facilitate comparison across species, mouse gene identifiers were re-annotated with human  
928 Ensembl gene orthologs using biomaRt, an R interface with the Biomart database  
929 ([www.biomart.org](http://www.biomart.org)). Only identifiers that were common to both human and mouse meta-sets  
930 were retained. A consensus network represents a single network arising from multiple sources

931 of data constructed from the weighted average of correlation matrices from both the human  
932 and mouse in this study. By definition, consensus modules are the branches of a clustering  
933 tree developed from a consensus gene dissimilarity, comparable to the single-network  
934 approach; consensus modules contain genes that are closely related in both networks, i.e., the  
935 modules are present in both networks. After scaling the network (consensus scaling  
936 quantile=0.2), a threshold power of 14 was chosen (as the smallest threshold resulting in a  
937 scale-free  $R^2$  fit of 0.9). The consensus tree was then built which identified 4 modules for which  
938 correlation to phenotype (ALS) and adjusted-pvalue (FDR) were calculated. This approach led  
939 to the identification of a final set of 4 modules.

940

#### 941 Violin plot of eigengene expression

942 For each module and corresponding cell type, the module eigengene was calculated in control  
943 and ALS conditions using the moduleEigengenes() function. Comparison across conditions  
944 was calculated using a Wilcoxon rank-sum test and considered significant when Bonferroni  
945 corrected p-value < 0.05.

946

#### 947 **ENCODE RNA-binding proteins (RBP) knock-down experiments**

948 A list of 217 RBPs and their counts files were downloaded from the ENCODE consortium  
949 (<https://www.encodeproject.org/>). Counts files for each RBPs were downloaded and  
950 normalized to library size and internal controls. A final list of 217 RBPs was used to calculate  
951 the eigengene expression of the FUS regulon. Each RBPs was then ranked according to the  
952 magnitude of the FUS regulon dysregulation.

953

#### 954 **Olink proteogenomics study cohort**

955 Olink proteomic profiling was conducted on blood plasma samples collected from 54,967 UK  
956 Biobank participants using the Olink Explore 3072 platform. This platform measured 2,923  
957 protein analytes, reflecting 2,941 unique proteins measured across the Olink panels that  
958 comprise the 3072 panel. For whole-exome sequencing-based proteogenomic analyses, we  
959 analyzed the 52,217 samples with available paired-exome sequence data. We identified the  
960 participants with European genetic ancestry based on HapMap projection. We performed finer-  
961 scale ancestry pruning of these individuals, retaining those within 4 s.d. from the mean across  
962 the first four principal components, resulting in a final cohort of 46,327 individuals for the  
963 proteogenomic analyses. Finally, we built metadata on neurodegenerative diseases diagnosed  
964 after enrollment (AD, PD, ALS, VaD, AD) and carriers' status of *FBXO16* PTV (*FBXO16*). We  
965 filtered individuals to have age-and sex matched controls for each disease resulting in a final  
966 cohort of 24,557 individuals. To ensure a minimum number of observations per group,  
967 proteins with a high fraction of missing values (>75% of participants) were excluded from the  
968 regression analysis. In addition, groupwise outlier removal of protein measurements ( $\pm 1.5 \times$   
969 IQR) was performed before regression analysis because the presence of outliers can severely  
970 affect the resulting test statistics, potentially increasing the rate of false negatives in the initial  
971 biomarker discovery phase. Linear regression adjusted for age and sex, was performed for  
972 each protein and disease. Genome-wide significant association was set at Bonferroni  
973 corrected p-value < 0.05 / 2,941.

974

#### 975 **Brain MRI UK Biobank data acquisition**

976 UK Biobank brain imaging has been described as a resource (Miller et al., 2016), where the  
977 reader can find a number of examples describing how it can be accessed and used for  
978 research. Three dedicated imaging centers are equipped with identical scanners (3T Siemens  
979 Skyra, software VD13) for brain imaging scanning using the standard Siemens 32-channel  
980 receive head coil. The brain MRI protocol is performed using a 3 Tesla Siemens Skyra scanner  
981 (Siemens Healthineers, Erlangen, Germany) with VD13 software and a 32-channel head coil.  
982 The protocol includes three structural MRI scans; T1, T2 fluid attenuation inversion recovery  
983 (FLAIR) and susceptibility-weighted MRI (swMRI), as well as diffusion MRI (dMRI) and resting

984 and task functional MRI (fMRI). T1 scans allow precise volumetric measures of the whole brain,  
985 as well as specific cortical and subcortical regions. An automated processing pipeline for brain  
986 image analysis and quality control was established for UKB at the University of Oxford's  
987 Wellcome Centre for Integrative Neuroimaging (WIN/FMRIB). This pipeline is primarily based  
988 around FSL (FMRIB's Software Library), and other packages such as FreeSurfer. When  
989 acquired at the imaging center, the images are reconstructed from *k*-space on the scanner  
990 computer and saved initially as DICOM files. The processing pipeline then converts these files  
991 to the NIFTI format and undertakes pre-processing (e.g., correcting for head motion and other  
992 artefacts) as well as automated quality control that identifies issue with the equipment (e.g.,  
993 coil failure) and artefacts specific to the participant or scanning session (e.g., excessive head  
994 movement). The NIFTI files for the T1 are provided to researchers, as these are suitably  
995 "defaced" to remove the possibility of re-identification of any individual participant. The pipeline  
996 also automatically generates thousands of IDPs, such as regional grey matter volume from T1  
997 scans, fractional anisotropy, axial diffusivity and mean diffusivity measures from dMRI scans.  
998 These IDPs have been made available to researchers with authorized access and were used  
999 for GWAS association with FBXO16 carriers' status.

1000

### 1001 **Grey matter volume, area and thickness analysis in *FBXO16* PTV carriers**

1002 Grey matter volumes, area and thickness were produced using the *recon-all* script, in cross-  
1003 sectional mode, of FreeSurfer version 5.3 (Fischl, 2012) on each T1-weighted scan. The  
1004 standard pre-processing steps of the FreeSurfer image analysis suite were first implemented,  
1005 including removal of non-brain tissue, segmentation of the subcortical white matter and deep  
1006 grey matter structures, intensity normalization, tessellation of the grey matter–white matter  
1007 boundary, and automated topology correction. Following quality control steps for segmentation  
1008 accuracy, overall volumes of cortical structures and total intracranial volume estimates (eTIV)  
1009 were retrieved from each subject. A dual pipeline was implemented exploring cortical thickness  
1010 alterations and morphometric changes using voxel-based morphometry (VBM). Following pre-  
1011 processing and cortical segmentation in FreeSurfer, average cortical thickness, volume and  
1012 area values have been retrieved from 34 cortical regions in each hemisphere separately as  
1013 per the Desikan–Killiany atlas (Desikan et al., 2006). Cortical thickness values in the following  
1014 lobes and corresponding subregions regions were appraised, Frontal lobe (13 ROIs): Superior  
1015 Frontal, Rostral and Caudal Middle Frontal, Pars Opercularis, Pars Triangularis, and Pars  
1016 Orbitalis, Lateral and Medial Orbitofrontal, Precentral, Paracentral, Frontal Pole, Rostral  
1017 Anterior cingulate, Caudal Anterior cingulate, Parietal lobe (7 ROIs): Superior Parietal, Inferior  
1018 Parietal, Supramarginal, Postcentral, Precuneus, Posterior cingulate, cingulate isthmus,  
1019 Temporal lobe (9 ROIs): Superior, Middle, and Inferior Temporal, Banks of the Superior  
1020 Temporal Sulcus, Fusiform, Transverse Temporal, Entorhinal, Temporal Pole,  
1021 Parahippocampal, Occipital lobe (4 ROIs): lateral Occipital, Lingual, Cuneus, Pericalcarine,  
1022 and the Insula (1 ROI). In addition to cortical thickness analyses, voxel-based morphometry  
1023 was also performed to evaluate anatomical patterns of signal intensity reductions in mutation  
1024 carriers. Regional effects of FBXO16 PTV status on cortical thickness, area and volume were  
1025 tested by general linear models (GLM) across the entire cortex controlling for age and sex.  
1026 Permutation-based non-parametric inference and the threshold-free cluster enhancement  
1027 (TFCE) approach were used to test for differences between study groups and significance was  
1028 set at  $FDR < 0.05$

1029

### 1030 **Connectometry**

1031 For DTI preprocessing of brain MRI, the DSI Studio software (version May 2024, [http://dsi-](http://dsi-studio.labsolver.org)  
1032 [studio.labsolver.org](http://dsi-studio.labsolver.org)) was utilized. This program, equipped with open-source images,  
1033 addressed eddy current and phase distortion artefacts, generated a mask through  
1034 thresholding, smoothing, and defragmentation, and underwent a quality control step for DTI.  
1035 Subsequently, diffusion data were reconstructed using the DTI method and generalized q-  
1036 sampling imaging (GQI) with a diffusion sampling length ratio of 1.25 (Yeh et al., 2010). The

1037 connectometry analysis incorporated DTI-based metrics, including FA, MD, AD, and RD  
1038 values, and GQI-based QA values, extracted as the local connectome fingerprint (Yeh et al.,  
1039 2016) When correlated with the apnea-hypopnea index (AHI), a representative measure of  
1040 OSA severity, diffusion MRI connectometry demonstrated changes in FA, MD, AD, RD, and  
1041 QA values. Non-parametric Spearman partial correlation, removing the effects of sex and age  
1042 via a multiple regression model, was used to derive these correlations. A T-score threshold of  
1043 2.5 guided deterministic fiber tracking for correlational tractography.  
1044

#### 1045 **LD-score regression and partitioned heritability for ALS**

1046 We used the summary association statistics from the latest GWAS of ALS (van Rheenen et  
1047 al., 2021). FUS regulon genes were mapped on single nuclei ATACseq data on major brain  
1048 cell types (Corces et al., 2020) leading to 17,280 cell type-specific ATAC peaks associated  
1049 with the FUS regulon (n=738 genes). As a positive control, we used the latest ALS GWAS and  
1050 extracted SNP with suggestive association with ALS ( $p < 5 \cdot 10^{-6}$ ). Each SNP were mapped to  
1051 the snATACseq using the same procedure leading to 13,278 ATAC peaks used as input to  
1052 ALS-GWAS LDSC analysis. As a negative control, we randomly selected 15,000 ATAC peaks  
1053 in a pool of 252,276 non-overlapping peaks across 6 major brain cell types. For each of the  
1054 above-created sets, we ran S-LDSC (Finucane et al., 2018) to generate the LD score of each  
1055 variant in each annotation using the same procedure. Regression SNPs, that are used by S-  
1056 LDSC to estimate  $\tau$  from marginal association statistics, were obtained from the HapMap  
1057 Project phase (International HapMap, 2003). Using the LD score for each annotation and the  
1058 marginal statistics obtained from the trait phenotypes (GWAS-ALS), we computed the  
1059 enrichment and calculated the p-value for each annotation (Finucane et al., 2018).  
1060

#### 1061 **GWAS of ALS-bi/ci in the AnswerALS cohort**

1062 Whole genome sequencing from 631 ALS patients from the AnswerALS cohorts used were  
1063 preprocessed for GWAS analysis (Baxi et al., 2022). Duplicate individuals were removed (king-  
1064 cutoff=0.084). Population structure was assessed by projecting 1000 G principal components  
1065 (PCs) and outliers from the European ancestry population were removed ( $>4$  SD on PC1-4).  
1066 In total, 546 ALS cases passed quality check analysis. WGS SNPs variants were mapped to  
1067 genes using the SNP-to-Gene approach as described in MAGMA (de Leeuw et al., 2015)  
1068 leading to a final set of 143,188 variants used for GWAS analysis. After quality control, a null  
1069 logistic mixed model was fitted using PLINK with principal component (PC)1–PC10, sex, age  
1070 at onset and APOE genotype as covariates. To assess any residual confounding due to  
1071 population stratification and artificial structure in the data, we calculated the LDSC intercept  
1072 using SNP LD scores calculated in the HapMap3 CEU population. Genome-wide significance  
1073 was set at  $5 \cdot 10^{-7}$ .  
1074

#### 1075 **Statistics**

1076 Values from each animal were averaged for each genotype group and data are expressed as  
1077 mean  $\pm$  standard error of the mean (SEM). Statistical analysis was performed using the  
1078 GraphPad Prism 8 software with a significant threshold set at  $p < 0.05$ . Analysis of variance  
1079 (ANOVA) was used because it was justified by the independence and normality of results and  
1080 the equality of variances. Details of the analyses are systematically given in the figure legends.  
1081 Normality and homoscedasticity were both assessed prior to analysis using Shapiro-Wilk and  
1082 Bartlett's test, respectively. Statistical analysis of two groups were performed using  
1083 independent Student's t-tests with Statsmodels package  
1084  
1085

1086 **Resource availability**

1087 All snRNAseq datasets have been deposited on GEO.

1088 *Fus*<sup>exon15</sup> mice are available upon request to the corresponding authors.

1089

1090 **Acknowledgements**

1091 The authors would like to thank the technicians of the animal facilities, namely Célian Pitard,  
1092 Christiane Rieger and Claudia Spielmann, for their care of the mice. We are grateful to  
1093 PICSTRA Imaging platform (UMS38, CRBS) and PEFRE animal facility platform (UMS38,  
1094 CRBS for technical assistance and support. We acknowledge all persons involved in the  
1095 mouse generation project at the ICS (Strasbourg, France) for their assistance with project  
1096 design and data analysis. This work was supported in part by the Intramural Research Program  
1097 of the National Institutes of Health, the National Institute on Aging (1ZIAAG000933). This work  
1098 was funded by Agence Nationale de la Recherche (ANR-16-CE92-0031, ANR-19-CE17-0016,  
1099 ANR-20-CE17-0008, ANR-21-CE17-0039, ANR-24-CE37-4064), by the Interdisciplinary  
1100 Thematic Institute NeuroStra, as part of the ITI 2021-2028 (Idex Unistra ANR-10-IDEX-0002,  
1101 ANR-20-SFRI-0012) by Fondation Bettencourt (Coup d'élan 2019 to LD), Fondation pour la  
1102 recherche médicale (FRM, DEQ20180339179), Axa Research Funds (rare diseases award  
1103 2019, to LD), Association Française de Recherche sur la sclérose latérale amyotrophique, the  
1104 Association Française contre les Myopathies (AFM-Téléthon, #23646, #28944)). LD is USIAS  
1105 fellow 2019).

1106

1107 **Author contributions**

1108 Mouse breeding genotyping were performed by C.D.T., S.D. and R.C. Mouse tissues were  
1109 processed by R.C., F.L. and A.B. Histological analysis in mice was conducted by R.C., F.L.,  
1110 A.B, and P.K. The *Fus* mouse model generation was conducted by M-C.B. Behavioral tests  
1111 were conducted by R.C., F.L., A.B, and C.D, while the analysis was performed by R.C and  
1112 S.D. EEG surgery and analysis were performed by S.J.G. and G.S.L. Single-nucleus RNA  
1113 sequencing analysis, cross-species integration, genetic analyses, and UK Biobank data mining  
1114 were conducted by S.M. Human Pathology was performed by F.M.W. and J.M.G.. SnRNAseq  
1115 of ALS and ALS-ci patients was performed and analyzed by S.M., C.G.R., C.A.J. and H.P..  
1116 B.T., A.C., R.R. and J.S. contributed with clinical and genetic data as well as research tools.  
1117 Funding was secured by R.C. and L.D. The work was conceptualized, coordinated and  
1118 supervised by R.C., LD and SM. The manuscript was written by R.C, L.D. and S.M.

1119

1120 **Declaration of interests**

1121 BJT has a patent pending (U.S. Patent Application No. 63/717,807) on the diagnostic testing  
1122 for ALS based on a proteomic panel. BJT holds patents on the clinical testing and therapeutic  
1123 intervention for the hexanucleotide repeat expansion of *C9orf72*. BJT receives research  
1124 support from Cerevel Therapeutics.

1125

1126 **Supplemental information**

1127 Document with Figures S1–S8.

1128 Tables S1 & S2.

1129

1130 **References**

- 1131
- 1132 Abrahams, S. (2023). Neuropsychological impairment in amyotrophic lateral sclerosis-  
1133 frontotemporal spectrum disorder. *Nat Rev Neurol* 19, 655-667.
- 1134 Aguzzoli, C.S., Battista, P., Hadad, R., Ferreira Felloni Borges, Y., Schilling, L.P., and Miller,  
1135 B.L. (2022). Very early-onset behavioral variant frontotemporal dementia in a patient  
1136 with a variant of uncertain significance of a FUS gene mutation. *Neurocase* 28, 403-409.
- 1137 Bakken, T.E., Jorstad, N.L., Hu, Q., Lake, B.B., Tian, W., Kalmbach, B.E., Crow, M., Hodge,  
1138 R.D., Krienen, F.M., Sorensen, S.A., *et al.* (2021). Comparative cellular analysis of motor  
1139 cortex in human, marmoset and mouse. *Nature* 598, 111-119.
- 1140 Bampton, A., McHutchison, C., Talbot, K., Benatar, M., Thompson, A.G., and Turner, M.R.  
1141 (2024). The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral  
1142 Sclerosis. *Brain Behav* 14, e70115.
- 1143 Baxi, E.G., Thompson, T., Li, J., Kaye, J.A., Lim, R.G., Wu, J., Ramamoorthy, D., Lima, L.,  
1144 Vaibhav, V., Matlock, A., *et al.* (2022). Answer ALS, a large-scale resource for sporadic  
1145 and familial ALS combining clinical and multi-omics data from induced pluripotent cell  
1146 lines. *Nat Neurosci* 25, 226-237.
- 1147 Bellmann, J., Monette, A., Tripathy, V., Sojka, A., Abo-Rady, M., Janosh, A., Bhatnagar, R.,  
1148 Bickle, M., Moulard, A.J., and Sternecker, J. (2019). Viral Infections Exacerbate FUS-  
1149 ALS Phenotypes in iPSC-Derived Spinal Neurons in a Virus Species-Specific Manner.  
1150 *Frontiers in cellular neuroscience* 13, 480.
- 1151 Bosco, D.A., Lemay, N., Ko, H.K., Zhou, H., Burke, C., Kwiatkowski, T.J., Jr., Sapp, P.,  
1152 McKenna-Yasek, D., Brown, R.H., Jr., and Hayward, L.J. (2010). Mutant FUS proteins  
1153 that cause amyotrophic lateral sclerosis incorporate into stress granules. *Hum Mol*  
1154 *Genet* 19, 4160-4175.
- 1155 Broustal, O., Camuzat, A., Guillot-Noel, L., Guy, N., Millecamps, S., Deffond, D., Lacomblez,  
1156 L., Golfier, V., Hannequin, D., Salachas, F., *et al.* (2010). FUS mutations in  
1157 frontotemporal lobar degeneration with amyotrophic lateral sclerosis. *J Alzheimers Dis*  
1158 22, 765-769.
- 1159 Brown, A.L., Wilkins, O.G., Keuss, M.J., Hill, S.E., Zanovello, M., Lee, W.C., Bampton, A.,  
1160 Lee, F.C.Y., Masino, L., Qi, Y.A., *et al.* (2022). TDP-43 loss and ALS-risk SNPs drive  
1161 mis-splicing and depletion of UNC13A. *Nature*.
- 1162 Brown, R.H., Jr., and Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. *N Engl J Med*  
1163 377, 162-172.
- 1164 Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia Working  
1165 Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L., and Neale,  
1166 B.M. (2015). LD Score regression distinguishes confounding from polygenicity in  
1167 genome-wide association studies. *Nat Genet* 47, 291-295.
- 1168 Carlson, C.G., Rutter, J., Bledsoe, C., Singh, R., Hoff, H., Bruemmer, K., Sesti, J., Gatti, F.,  
1169 Berge, J., and McCarthy, L. (2010). A simple protocol for assessing inter-trial and inter-  
1170 examiner reliability for two noninvasive measures of limb muscle strength. *J Neurosci*  
1171 *Methods* 186, 226-230.
- 1172 Caroni, P. (1997). Overexpression of growth-associated proteins in the neurons of adult  
1173 transgenic mice. *J Neurosci Methods* 71, 3-9.
- 1174 Chen, K., Gao, T., Liu, Y., Zhu, K., Wang, T., and Zeng, P. (2024). Identifying risk loci for  
1175 FTD and shared genetic component with ALS: A large-scale multitrait association  
1176 analysis. *Neurobiol Aging* 134, 28-39.
- 1177 Cheng, Y.Y., Chou, Y.T., Lai, F.J., Jan, M.S., Chang, T.H., Jou, I.M., Chen, P.S., Lo, J.Y.,  
1178 Huang, S.S., Chang, N.S., *et al.* (2020). Wwox deficiency leads to neurodevelopmental  
1179 and degenerative neuropathies and glycogen synthase kinase 3beta-mediated epileptic  
1180 seizure activity in mice. *Acta Neuropathol Commun* 8, 6.
- 1181 Corces, M.R., Shcherbina, A., Kundu, S., Gloudemans, M.J., Fresard, L., Granja, J.M.,  
1182 Louie, B.H., Eulalio, T., Shams, S., Bagdatli, S.T., *et al.* (2020). Single-cell epigenomic

- 1183 analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and  
1184 Parkinson's diseases. *Nat Genet* *52*, 1158-1168.
- 1185 D'Anna, L., Mesulam, M.M., Thiebaut de Schotten, M., Dell'Acqua, F., Murphy, D., Wieneke,  
1186 C., Martersteck, A., Cobia, D., Rogalski, E., and Catani, M. (2016). Frontotemporal  
1187 networks and behavioral symptoms in primary progressive aphasia. *Neurology* *86*, 1393-  
1188 1399.
- 1189 De Decker, M., Zelina, P., Moens, T.G., Beckers, J., Contardo, M., Dittlau, K.S., Van Schoor,  
1190 E., Ronisz, A., Eggermont, K., Moisse, M., *et al.* (2025). C21ORF2 mutations point  
1191 towards primary cilia dysfunction in amyotrophic lateral sclerosis. *Brain* *148*, 803-816.
- 1192 de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized  
1193 gene-set analysis of GWAS data. *PLoS Comput Biol* *11*, e1004219.
- 1194 Deacon, R.M. (2006). Assessing nest building in mice. *Nature protocols* *1*, 1117-1119.
- 1195 Desikan, R.S., Segonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., Buckner,  
1196 R.L., Dale, A.M., Maguire, R.P., Hyman, B.T., *et al.* (2006). An automated labeling  
1197 system for subdividing the human cerebral cortex on MRI scans into gyral based regions  
1198 of interest. *Neuroimage* *31*, 968-980.
- 1199 Diekstra, F.P., Van Deerlin, V.M., van Swieten, J.C., Al-Chalabi, A., Ludolph, A.C.,  
1200 Weishaupt, J.H., Hardiman, O., Landers, J.E., Brown, R.H., Jr., van Es, M.A., *et al.*  
1201 (2014). C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and  
1202 frontotemporal dementia: a genome-wide meta-analysis. *Ann Neurol* *76*, 120-133.
- 1203 Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M.E.,  
1204 Mackenzie, I.R., Capell, A., Schmid, B., *et al.* (2010). ALS-associated fused in sarcoma  
1205 (FUS) mutations disrupt Transportin-mediated nuclear import. *EMBO J* *29*, 2841-2857.
- 1206 Dugan, A.J., Nelson, P.T., Katsumata, Y., Shade, L.M.P., Teylan, M.A., Boehme, K.L.,  
1207 Mukherjee, S., Kauwe, J.S.K., Hohman, T.J., Schneider, J.A., *et al.* (2022). Association  
1208 between WWOX/MAF variants and dementia-related neuropathologic endophenotypes.  
1209 *Neurobiol Aging* *111*, 95-106.
- 1210 Dulski, J., Strongosky, A.J., Al-Shaikh, R.H., and Wszolek, Z.K. (2023). Expanding the  
1211 spectrum of KIF5A mutations-case report of a large kindred with familial ALS and  
1212 overlapping syndrome. *Amyotrophic lateral sclerosis & frontotemporal degeneration* *24*,  
1213 347-350.
- 1214 Elahi, F.M., Marx, G., Cobigo, Y., Staffaroni, A.M., Kornak, J., Tosun, D., Boxer, A.L.,  
1215 Kramer, J.H., Miller, B.L., and Rosen, H.J. (2017). Longitudinal white matter change in  
1216 frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease.  
1217 *Neuroimage Clin* *16*, 595-603.
- 1218 Feil, R., Wagner, J., Metzger, D., and Chambon, P. (1997). Regulation of Cre recombinase  
1219 activity by mutated estrogen receptor ligand-binding domains. *Biochem Biophys Res*  
1220 *Commun* *237*, 752-757.
- 1221 Finucane, H.K., Reshef, Y.A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S.,  
1222 Loh, P.R., Lareau, C., Shores, N., *et al.* (2018). Heritability enrichment of specifically  
1223 expressed genes identifies disease-relevant tissues and cell types. *Nat Genet* *50*, 621-  
1224 629.
- 1225 Fischl, B. (2012). FreeSurfer. *Neuroimage* *62*, 774-781.
- 1226 Forrest, S.L., and Kovacs, G.G. (2024). Current concepts and molecular pathology of  
1227 neurodegenerative diseases. *Pathology*.
- 1228 Gao, C., Gu, J., Zhang, H., Jiang, K., Tang, L., Liu, R., Zhang, L., Zhang, P., Liu, C., Dai, B.,  
1229 *et al.* (2022). Hyperosmotic-stress-induced liquid-liquid phase separation of ALS-related  
1230 proteins in the nucleus. *Cell Rep* *40*, 111086.
- 1231 Gascon, E., Lynch, K., Ruan, H., Almeida, S., Verheyden, J.M., Seeley, W.W., Dickson,  
1232 D.W., Petrucelli, L., Sun, D., Jiao, J., *et al.* (2014). Alterations in microRNA-124 and  
1233 AMPA receptors contribute to social behavioral deficits in frontotemporal dementia. *Nat*  
1234 *Med* *20*, 1444-1451.

- 1235 Goldstein, O., Inbar, T., Kedmi, M., Gana-Weisz, M., Abramovich, B., Orr-Urtreger, A., and  
1236 Drory, V.E. (2022). FUS-P525L Juvenile Amyotrophic Lateral Sclerosis and Intellectual  
1237 Disability: Evidence for Association and Oligogenic Inheritance. *Neurol Genet* *8*,  
1238 e200009.
- 1239 Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C., and  
1240 Feldman, E.L. (2022a). Emerging insights into the complex genetics and  
1241 pathophysiology of amyotrophic lateral sclerosis. *Lancet Neurol*.
- 1242 Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C., and  
1243 Feldman, E.L. (2022b). Recent advances in the diagnosis and prognosis of amyotrophic  
1244 lateral sclerosis. *Lancet Neurol*.
- 1245 Grassano, M., Brodini, G., De Marco, G., Casale, F., Fuda, G., Salamone, P., Brunetti, M.,  
1246 Sbaiz, L., Gallone, S., Cugnasco, P., *et al.* (2022). Phenotype Analysis of Fused in  
1247 Sarcoma Mutations in Amyotrophic Lateral Sclerosis. *Neurol Genet* *8*, e200011.
- 1248 Gregory, J.M., McDade, K., Bak, T.H., Pal, S., Chandran, S., Smith, C., and Abrahams, S.  
1249 (2020). Executive, language and fluency dysfunction are markers of localised TDP-43  
1250 cerebral pathology in non-demented ALS. *J Neurol Neurosurg Psychiatry* *91*, 149-157.
- 1251 Guillot, S.J. (2023). *EEVop* (sjg2203/EEVop: GitHub, Zenodo).
- 1252 Guillot, S.J., Lang, C., Simonot, M., Beckett, D., Lule, D., Balz, L.T., Knehr, A., Stuart-Lopez,  
1253 G., Vercruysse, P., Dieterle, S., *et al.* (2025). Early-onset sleep alterations found in  
1254 patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse  
1255 models. *Sci Transl Med* *17*, eadm7580.
- 1256 Guo, Y., You, J., Zhang, Y., Liu, W.S., Huang, Y.Y., Zhang, Y.R., Zhang, W., Dong, Q.,  
1257 Feng, J.F., Cheng, W., *et al.* (2024). Plasma proteomic profiles predict future dementia  
1258 in healthy adults. *Nat Aging* *4*, 247-260.
- 1259 Hirayanagi, K., Sato, M., Furuta, N., Makioka, K., and Ikeda, Y. (2016). Juvenile-onset  
1260 Sporadic Amyotrophic Lateral Sclerosis with a Frameshift FUS Gene Mutation  
1261 Presenting Unique Neuroradiological Findings and Cognitive Impairment. *Intern Med* *55*,  
1262 689-693.
- 1263 Hock, E.-M., Maniecka, Z., Hruska-Plochan, M., Reber, S., Laferriere, F., Sahadevan M K,  
1264 S., Ederle, H., Gittings, L., Pelkmans, L., Dupuis, L., *et al.* (2018). Hypertonic Stress  
1265 Causes Cytoplasmic Translocation of Neuronal, but Not Astrocytic, FUS due to Impaired  
1266 Transportin Function. *Cell reports* *24*, 987-1000.e1007.
- 1267 Humphrey, J., Birsa, N., Milioto, C., McLaughlin, M., Ule, A.M., Robaldo, D., Eberle, A.B.,  
1268 Krauchi, R., Bentham, M., Brown, A.L., *et al.* (2020). FUS ALS-causative mutations  
1269 impair FUS autoregulation and splicing factor networks through intron retention. *Nucleic  
1270 Acids Res* *48*, 6889-6905.
- 1271 International HapMap, C. (2003). The International HapMap Project. *Nature* *426*, 789-796.
- 1272 Irwin, D.J., Grossman, M., Weintraub, D., Hurtig, H.I., Duda, J.E., Xie, S.X., Lee, E.B., Van  
1273 Deerlin, V.M., Lopez, O.L., Kofler, J.K., *et al.* (2017). Neuropathological and genetic  
1274 correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.  
1275 *Lancet Neurol* *16*, 55-65.
- 1276 Isingrini, E., Camus, V., Le Guisquet, A.M., Pingaud, M., Devers, S., and Belzung, C. (2010).  
1277 Association between repeated unpredictable chronic mild stress (UCMS) procedures  
1278 with a high fat diet: a model of fluoxetine resistance in mice. *PLoS One* *5*, e10404.
- 1279 James, B.D., Wilson, R.S., Boyle, P.A., Trojanowski, J.Q., Bennett, D.A., and Schneider, J.A.  
1280 (2016). TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. *Brain*  
1281 *139*, 2983-2993.
- 1282 Jeong, Y.H., Ling, J.P., Lin, S.Z., Donde, A.N., Braunstein, K.E., Majounie, E., Traynor, B.J.,  
1283 LaClair, K.D., Lloyd, T.E., and Wong, P.C. (2017). Tdp-43 cryptic exons are highly  
1284 variable between cell types. *Mol Neurodegener* *12*, 13.
- 1285 Karanth, S., Nelson, P.T., Katsumata, Y., Kryscio, R.J., Schmitt, F.A., Fardo, D.W.,  
1286 Cykowski, M.D., Jicha, G.A., Van Eldik, L.J., and Abner, E.L. (2020). Prevalence and

- 1287 Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. *JAMA Neurol* 77,  
1288 1299-1307.
- 1289 Katisko, K., Cajanus, A., Huber, N., Jaaskelainen, O., Kokkola, T., Karkkainen, V., Rostalski,  
1290 H., Hartikainen, P., Koivisto, A.M., Hannonen, S., *et al.* (2021). GFAP as a biomarker in  
1291 frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic  
1292 performance. *J Neurol Neurosurg Psychiatry* 92, 1305-1312.
- 1293 Katsumata, Y., Abner, E.L., Karanth, S., Teylan, M.A., Mock, C.N., Cykowski, M.D., Lee,  
1294 E.B., Boehme, K.L., Mukherjee, S., Kauwe, J.S.K., *et al.* (2020). Distinct  
1295 clinicopathologic clusters of persons with TDP-43 proteinopathy. *Acta Neuropathol* 140,  
1296 659-674.
- 1297 Khan, M., Muzumdar, D., and Shiras, A. (2019). Attenuation of Tumor Suppressive Function  
1298 of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma. *Neoplasia* 21,  
1299 106-116.
- 1300 Kosla, K., Pluciennik, E., Styczen-Binkowska, E., Nowakowska, M., Orzechowska, M., and  
1301 Bednarek, A.K. (2019). The WWOX Gene Influences Cellular Pathways in the Neuronal  
1302 Differentiation of Human Neural Progenitor Cells. *Frontiers in cellular neuroscience* 13,  
1303 391.
- 1304 Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A.,  
1305 Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., *et al.* (2019). Genetic meta-analysis of  
1306 diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau,  
1307 immunity and lipid processing. *Nat Genet* 51, 414-430.
- 1308 Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C.,  
1309 Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., *et al.* (2009). Mutations in the  
1310 FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science*  
1311 323, 1205-1208.
- 1312 Lagier-Tourenne, C., Polymenidou, M., and Cleveland, D.W. (2010). TDP-43 and FUS/TLS:  
1313 emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* 19, R46-64.
- 1314 Lagier-Tourenne, C., Polymenidou, M., Hutt, K.R., Vu, A.Q., Baughn, M., Huelga, S.C.,  
1315 Clutario, K.M., Ling, S.C., Liang, T.Y., Mazur, C., *et al.* (2012). Divergent roles of ALS-  
1316 linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat*  
1317 *Neurosci* 15, 1488-1497.
- 1318 Lanteri, P., Meola, I., Canosa, A., De Marco, G., Lomartire, A., Rinaudo, M.T., Albamonte, E.,  
1319 Sansone, V.A., Lunetta, C., Manera, U., *et al.* (2021). The heterozygous deletion  
1320 c.1509\_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with  
1321 cognitive impairment. *Neurobiol Aging* 103, 130 e131-130 e137.
- 1322 Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva  
1323 package for removing batch effects and other unwanted variation in high-throughput  
1324 experiments. *Bioinformatics* 28, 882-883.
- 1325 Lin, Y.C., Kumar, M.S., Ramesh, N., Anderson, E.N., Nguyen, A.T., Kim, B., Cheung, S.,  
1326 McDonough, J.A., Skarnes, W.C., Lopez-Gonzalez, R., *et al.* (2021). Interactions  
1327 between ALS-linked FUS and nucleoporins are associated with defects in the  
1328 nucleocytoplasmic transport pathway. *Nat Neurosci*.
- 1329 Ling, J.P., Pletnikova, O., Troncoso, J.C., and Wong, P.C. (2015). TDP-43 repression of  
1330 nonconserved cryptic exons is compromised in ALS-FTD. *Science* 349, 650-655.
- 1331 Littlejohns, T.J., Holliday, J., Gibson, L.M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F.,  
1332 Bell, J.D., Boultonwood, C., Collins, R., Conroy, M.C., *et al.* (2020). The UK Biobank  
1333 imaging enhancement of 100,000 participants: rationale, data collection, management  
1334 and future directions. *Nat Commun* 11, 2624.
- 1335 Liu, E.Y., Russ, J., Cali, C.P., Phan, J.M., Amlie-Wolf, A., and Lee, E.B. (2019). Loss of  
1336 Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. *Cell Rep*  
1337 27, 1409-1421 e1406.
- 1338 Liu, G., Peng, J., Liao, Z., Locascio, J.J., Corvol, J.C., Zhu, F., Dong, X., Maple-Grodem, J.,  
1339 Campbell, M.C., Elbaz, A., *et al.* (2021). Genome-wide survival study identifies a novel


- 1340 synaptic locus and polygenic score for cognitive progression in Parkinson's disease. *Nat*  
1341 *Genet* 53, 787-793.
- 1342 Lueptow, L.M. (2017). Novel Object Recognition Test for the Investigation of Learning and  
1343 Memory in Mice. *J Vis Exp*.
- 1344 Luisier, R., Tyzack, G.E., Hall, C.E., Mitchell, J.S., Devine, H., Taha, D.M., Malik, B., Meyer,  
1345 I., Greensmith, L., Newcombe, J., *et al.* (2018). Intron retention and nuclear loss of  
1346 SFPQ are molecular hallmarks of ALS. *Nat Commun* 9, 2010.
- 1347 Ma, X.R., Prudencio, M., Koike, Y., Vatsavayai, S.C., Kim, G., Harbinski, F., Briner, A.,  
1348 Rodriguez, C.M., Guo, C., Akiyama, T., *et al.* (2022). TDP-43 represses cryptic exon  
1349 inclusion in the FTD-ALS gene UNC13A. *Nature*.
- 1350 Mackenzie, I.R., Ansorge, O., Strong, M., Bilbao, J., Zinman, L., Ang, L.C., Baker, M.,  
1351 Stewart, H., Eisen, A., Rademakers, R., *et al.* (2011a). Pathological heterogeneity in  
1352 amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with  
1353 disease severity and mutation. *Acta Neuropathol* 122, 87-98.
- 1354 Mackenzie, I.R., Munoz, D.G., Kusaka, H., Yokota, O., Ishihara, K., Roeber, S., Kretschmar,  
1355 H.A., Cairns, N.J., and Neumann, M. (2011b). Distinct pathological subtypes of FTLD-  
1356 FUS. *Acta Neuropathol* 121, 207-218.
- 1357 Mahoney, C.J., Simpson, I.J., Nicholas, J.M., Fletcher, P.D., Downey, L.E., Golden, H.L.,  
1358 Clark, C.N., Schmitz, N., Rohrer, J.D., Schott, J.M., *et al.* (2015). Longitudinal diffusion  
1359 tensor imaging in frontotemporal dementia. *Ann Neurol* 77, 33-46.
- 1360 Maldonado-Diaz, C., Hiya, S., Yokoda, R.T., Farrell, K., Marx, G.A., Kauffman, J., Daoud,  
1361 E.V., Gonzales, M.M., Parker, A.S., Canbeldek, L., *et al.* (2024). Disentangling and  
1362 quantifying the relative cognitive impact of concurrent mixed neurodegenerative  
1363 pathologies. *Acta Neuropathol* 147, 58.
- 1364 Mallaret, M., Synofzik, M., Lee, J., Sagum, C.A., Mahajnah, M., Sharkia, R., Drouot, N.,  
1365 Renaud, M., Klein, F.A., Anheim, M., *et al.* (2014). The tumour suppressor gene WWOX  
1366 is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation.  
1367 *Brain* 137, 411-419.
- 1368 Megat, S., Mora, N., Sanogo, J., Roman, O., Catanese, A., Alami, N.O., Freischmidt, A.,  
1369 Mingaj, X., De Calbiac, H., Muratet, F., *et al.* (2023). Integrative genetic analysis  
1370 illuminates ALS heritability and identifies risk genes. *Nat Commun* 14, 342.
- 1371 Miller, K.L., Alfaro-Almagro, F., Bangerter, N.K., Thomas, D.L., Yacoub, E., Xu, J., Bartsch,  
1372 A.J., Jbabdi, S., Sotiropoulos, S.N., Andersson, J.L., *et al.* (2016). Multimodal population  
1373 brain imaging in the UK Biobank prospective epidemiological study. *Nat Neurosci* 19,  
1374 1523-1536.
- 1375 Moens, T.G., Da Cruz, S., Neumann, M., Shelkownikova, T.A., Shneider, N.A., and Van Den  
1376 Bosch, L. (2025). Amyotrophic lateral sclerosis caused by FUS mutations: advances with  
1377 broad implications. *Lancet Neurol* 24, 166-178.
- 1378 Munoz-Neira, C., Tedde, A., Coulthard, E., Thai, N.J., and Pennington, C. (2019). Neural  
1379 correlates of altered insight in frontotemporal dementia: a systematic review.  
1380 *Neuroimage Clin* 24, 102066.
- 1381 Network, B.I.C.C. (2021). A multimodal cell census and atlas of the mammalian primary  
1382 motor cortex. *Nature* 598, 86-102.
- 1383 Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., Ansorge,  
1384 O., Roeber, S., Kretschmar, H.A., Munoz, D.G., Kusaka, H., *et al.* (2011). FET proteins  
1385 TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from  
1386 amyotrophic lateral sclerosis with FUS mutations. *Brain* 134, 2595-2609.
- 1387 Paul, D., Islam, S., Manne, R.K., Dinesh, U.S., Malonia, S.K., Maity, B., Boppana, R.,  
1388 Rapole, S., Shetty, P.K., and Santra, M.K. (2019). F-box protein FBXO16 functions as a  
1389 tumor suppressor by attenuating nuclear beta-catenin function. *J Pathol* 248, 266-279.
- 1390 Petrescu, J., Roque, C.G., Jackson, C.A., Daly, A., Kang, K., Casel, O., Leung, M., Reilly, L.,  
1391 Eschbach, J., McDade, K., *et al.* (2025). Differential Cellular Mechanisms Underlie

- 1392 Language and Executive Decline in Amyotrophic Lateral Sclerosis. *bioRxiv*,  
1393 2025.2002.2026.640433.
- 1394 Picchiarelli, G., Demestre, M., Zuko, A., Been, M., Higelin, J., Dieterle, S., Goy, M.A., Mallik,  
1395 M., Sellier, C., Scekcic-Zahirovic, J., *et al.* (2019). FUS-mediated regulation of  
1396 acetylcholine receptor transcription at neuromuscular junctions is compromised in  
1397 amyotrophic lateral sclerosis. *Nat Neurosci*.
- 1398 Pineda, S.S., Lee, H., Ulloa-Navas, M.J., Linville, R.M., Garcia, F.J., Galani, K., Engelberg-  
1399 Cook, E., Castanedes, M.C., Fitzwalter, B.E., Pregent, L.J., *et al.* (2024). Single-cell  
1400 dissection of the human motor and prefrontal cortices in ALS and FTLD. *Cell* *187*, 1971-  
1401 1989 e1916.
- 1402 Piol, D., Robberechts, T., and Da Cruz, S. (2023). Lost in local translation: TDP-43 and FUS  
1403 in axonal/neuromuscular junction maintenance and dysregulation in amyotrophic lateral  
1404 sclerosis. *Neuron* *111*, 1355-1380.
- 1405 Repudi, S., Steinberg, D.J., Elazar, N., Breton, V.L., Aquilino, M.S., Saleem, A., Abu-Swai,  
1406 S., Vainshtein, A., Eshed-Eisenbach, Y., Vijayaragavan, B., *et al.* (2021). Neuronal  
1407 deletion of *Wwox*, associated with WOREE syndrome, causes epilepsy and myelin  
1408 defects. *Brain* *144*, 3061-3077.
- 1409 Rifai, O.M., Longden, J., O'Shaughnessy, J., Sewell, M., Pate, J., McDade, K., Daniels, M.J.,  
1410 Abrahams, S., Chandran, S., McColl, B.W., *et al.* (2022). Random forest modelling  
1411 demonstrates microglial and protein misfolding features to be key phenotypic markers in  
1412 C9orf72-ALS. *J Pathol* *258*, 366-381.
- 1413 Rifai, O.M., Waldron, F.M., O'Shaughnessy, J., Read, F.L., Gilodi, M., Pastore, A., Shneider,  
1414 N., Tartaglia, G.G., Zacco, E., Spence, H., *et al.* (2024). Amygdala TDP-43 pathology is  
1415 associated with behavioural dysfunction and ferritin accumulation in amyotrophic lateral  
1416 sclerosis. *bioRxiv*.
- 1417 Robinson, J.L., Xie, S.X., Baer, D.R., Suh, E., Van Deerlin, V.M., Loh, N.J., Irwin, D.J.,  
1418 McMillan, C.T., Wolk, D.A., Chen-Plotkin, A., *et al.* (2023). Pathological combinations in  
1419 neurodegenerative disease are heterogeneous and disease-associated. *Brain* *146*,  
1420 2557-2569.
- 1421 Rogelj, B., Easton, L.E., Bogu, G.K., Stanton, L.W., Rot, G., Curk, T., Zupan, B., Sugimoto,  
1422 Y., Modic, M., Haberman, N., *et al.* (2012). Widespread binding of FUS along nascent  
1423 RNA regulates alternative splicing in the brain. *Sci Rep* *2*, 603.
- 1424 Saez-Atienzar, S., Dalgard, C.L., Ding, J., Chio, A., Alba, C., Hupaló, D.N., Wilkerson, M.D.,  
1425 Bowser, R., Pioro, E.P., Bedlack, R., *et al.* (2020). Identification of a pathogenic intronic  
1426 KIF5A mutation in an ALS-FTD kindred. *Neurology* *95*, 1015-1018.
- 1427 Sanjuan-Ruiz, I., Govea-Perez, N., McAlonis-Downes, M., Dieterle, S., Megat, S., Dirrig-  
1428 Grosch, S., Picchiarelli, G., Piol, D., Zhu, Q., Myers, B., *et al.* (2021). Wild-type FUS  
1429 corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation.  
1430 *Mol Neurodegener* *16*, 61.
- 1431 Scekcic-Zahirovic, J., Benetton, C., Brunet, A., Ye, X., Logunov, E., Douchamps, V., Megat,  
1432 S., Andry, V., Kan, V.W.Y., Stuart-Lopez, G., *et al.* (2024). Cortical hyperexcitability in  
1433 mouse models and patients with amyotrophic lateral sclerosis is linked to noradrenaline  
1434 deficiency. *Sci Transl Med* *16*, eadg3665.
- 1435 Scekcic-Zahirovic, J., El Oussini, H., Mersmann, S., Drenner, K., Wagner, M., Sun, Y.,  
1436 Allmeroth, K., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., *et al.* (2017). Motor neuron  
1437 intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated  
1438 amyotrophic lateral sclerosis. *Acta Neuropathol (Berl)* *133*, 887-906.
- 1439 Scekcic-Zahirovic, J., Sanjuan-Ruiz, I., Kan, V., Megat, S., De Rossi, P., Dieterle, S., Cassel,  
1440 R., Jamet, M., Kessler, P., Wiesner, D., *et al.* (2021). Cytoplasmic FUS triggers early  
1441 behavioral alterations linked to cortical neuronal hyperactivity and inhibitory synaptic  
1442 defects. *Nat Commun* *12*, 3028.
- 1443 Scekcic-Zahirovic, J., Sendscheid, O., El Oussini, H., Jambeau, M., Sun, Y., Mersmann, S.,  
1444 Wagner, M., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., *et al.* (2016). Toxic gain of

- 1445 function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss.  
1446 *EMBO J* 35, 1077-1097.
- 1447 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,  
1448 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source  
1449 platform for biological-image analysis. *Nature methods* 9, 676-682.
- 1450 Serchov, T., van Calker, D., and Biber, K. (2016). Sucrose Preference Test to Measure  
1451 Anhedonic Behaviour in Mice. *Bio-protocol* 6, e1958.
- 1452 Shelkownikova, T.A., An, H., Skelt, L., Tregoning, J.S., Humphreys, I.R., and Buchman, V.L.  
1453 (2019). Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic  
1454 Lateral Sclerosis. *Cell Rep* 29, 4496-4508 e4494.
- 1455 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,  
1456 Green, J., Landray, M., *et al.* (2015). UK biobank: an open access resource for  
1457 identifying the causes of a wide range of complex diseases of middle and old age. *PLoS*  
1458 *Med* 12, e1001779.
- 1459 Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.H., Richardson, T.G., Surendran, P.,  
1460 Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., *et al.* (2023). Plasma proteomic  
1461 associations with genetics and health in the UK Biobank. *Nature* 622, 329-338.
- 1462 Sun, L., Cheng, B., Zhou, Y., Fan, Y., Li, W., Qiu, Q., Fang, Y., Xiao, S., Zheng, H., and Li,  
1463 X. (2020). ErbB4 Mutation that Decreased NRG1-ErbB4 Signaling Involved in the  
1464 Pathogenesis of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. *J Alzheimers*  
1465 *Dis* 74, 535-544.
- 1466 Suzuki, Y., Adachi, T., Yoshida, K., Sakuwa, M., and Hanajima, R. (2024). Psychiatric  
1467 symptoms and TDP-43 pathology in amyotrophic lateral sclerosis. *J Neurol Sci* 466,  
1468 123249.
- 1469 Szewczyk, B., Gunther, R., Japtok, J., Frech, M.J., Naumann, M., Lee, H.O., and Hermann,  
1470 A. (2023). FUS ALS neurons activate major stress pathways and reduce translation as  
1471 an early protective mechanism against neurodegeneration. *Cell Rep* 42, 112025.
- 1472 Tetter, S., Arseni, D., Murzin, A.G., Buhidma, Y., Peak-Chew, S.Y., Garringer, H.J., Newell,  
1473 K.L., Vidal, R., Apostolova, L.G., Lashley, T., *et al.* (2024). TAF15 amyloid filaments in  
1474 frontotemporal lobar degeneration. *Nature* 625, 345-351.
- 1475 Tyzack, G.E., Luisier, R., Taha, D.M., Neeves, J., Modic, M., Mitchell, J.S., Meyer, I.,  
1476 Greensmith, L., Newcombe, J., Ule, J., *et al.* (2019). Widespread FUS mislocalization is  
1477 a molecular hallmark of amyotrophic lateral sclerosis. *Brain* 142, 2572-2580.
- 1478 Tyzack, G.E., Neeves, J., Crerar, H., Klein, P., Ziff, O., Taha, D.M., Luisier, R., Luscombe,  
1479 N.M., and Patani, R. (2021). Aberrant cytoplasmic intron retention is a blueprint for RNA  
1480 binding protein mislocalization in VCP-related amyotrophic lateral sclerosis. *Brain* 144,  
1481 1985-1993.
- 1482 Urwin, H., Josephs, K.A., Rohrer, J.D., Mackenzie, I.R., Neumann, M., Authier, A., Seelaar,  
1483 H., Van Swieten, J.C., Brown, J.M., Johannsen, P., *et al.* (2010). FUS pathology defines  
1484 the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. *Acta*  
1485 *Neuropathol* 120, 33-41.
- 1486 Van Langenhove, T., van der Zee, J., Slegers, K., Engelborghs, S., Vandenberghe, R.,  
1487 Gijssels, I., Van den Broeck, M., Mattheijssens, M., Peeters, K., De Deyn, P.P., *et al.*  
1488 (2010). Genetic contribution of FUS to frontotemporal lobar degeneration. *Neurology* 74,  
1489 366-371.
- 1490 Van Nostrand, E.L., Freese, P., Pratt, G.A., Wang, X., Wei, X., Xiao, R., Blue, S.M., Chen,  
1491 J.Y., Cody, N.A.L., Dominguez, D., *et al.* (2020). A large-scale binding and functional  
1492 map of human RNA-binding proteins. *Nature* 583, 711-719.
- 1493 van Rheenen, W., van der Spek, R.A.A., Bakker, M.K., van Vugt, J., Hop, P.J., Zwamborn,  
1494 R.A.J., de Klein, N., Westra, H.J., Bakker, O.B., Deelen, P., *et al.* (2021). Common and  
1495 rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with  
1496 distinct genetic architectures and neuron-specific biology. *Nat Genet* 53, 1636-1648.

- 1497 Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X.,  
1498 Smith, B., Ruddy, D., Wright, P., *et al.* (2009). Mutations in FUS, an RNA processing  
1499 protein, cause familial amyotrophic lateral sclerosis type 6. *Science* *323*, 1208-1211.  
1500 Vazquez-Sanchez, S., Tilkin, B., Gasset-Rosa, F., Zhang, S., Piol, D., McAlonis-Downes, M.,  
1501 Artates, J., Govea-Perez, N., Verresen, Y., Guo, L., *et al.* (2024). Frontotemporal  
1502 dementia-like disease progression elicited by seeded aggregation and spread of FUS.  
1503 *Mol Neurodegener* *19*, 46.  
1504 Wang, Z., Liu, P., Inuzuka, H., and Wei, W. (2014). Roles of F-box proteins in cancer. *Nat*  
1505 *Rev Cancer* *14*, 233-247.  
1506 Yeh, F.C., Vettel, J.M., Singh, A., Poczos, B., Grafton, S.T., Erickson, K.I., Tseng, W.I., and  
1507 Verstynen, T.D. (2016). Quantifying Differences and Similarities in Whole-Brain White  
1508 Matter Architecture Using Local Connectome Fingerprints. *PLoS Comput Biol* *12*,  
1509 e1005203.  
1510 Yeh, F.C., Wedeen, V.J., and Tseng, W.Y. (2010). Generalized q-sampling imaging. *IEEE*  
1511 *Trans Med Imaging* *29*, 1626-1635.  
1512 Young, P., Qiu, L., Wang, D., Zhao, S., Gross, J., and Feng, G. (2008). Single-neuron  
1513 labeling with inducible Cre-mediated knockout in transgenic mice. *Nat Neurosci* *11*, 721-  
1514 728.  
1515  
1516

1517 **Figures and legends**



1518 **Figure 1: Cross-species transcriptomic analysis identifies *FUS*-related signature in**  
 1519 **vulnerable ALS neurons**  
 1520


1521 **A.** UMAP plot of the 78,514 cells split across 21 clusters identified in the frontal cortex of  
 1522 *Fus*<sup>ΔNLS/+</sup> mice

1523 **B.** UMAP plot of the 156,545 cells split across 19 clusters in the human M1 motor cortex.

1524 **C.** Cluster dendrogram, violin plots heatmaps and histogram plot shows number of genes  
 1525 detected, percent of each class (Glutamatergic, GABAergic and non-neurons), transcriptome-  
 1526 wide shift from controls in *Fus*<sup>ΔNLS/+</sup> mice and number of DE genes in each cell subclass.

1527 **D.** Cluster dendrogram, violin plots, heatmap and histogram bar plot shows number of genes  
 1528 detected, percent of each class (Glutamatergic, GABAergic and non-neurons), transcriptome-  
 1529 wide shift of ALS patients compared to healthy donors and number of DE genes in each cell  
 1530 subclass.

1531 **E-F:** Intersect plots show the number of DE genes in each excitatory subclass and overlap  
 1532 used to perform gene ontology analysis in mice and human. Histogram bar plot shows gene  
 1533 ontology terms enriched in all excitatory neurons of ALS patients and *Fus*<sup>ΔNLS/+</sup> mice.



1534  
1535 **Figure 2: Cell-type specific gene module analysis identifies conserved regulatory**  
1536 **networks associated with FUS, and shared with TDP-43.**

1537 **A.** Experimental design of the gene network analysis in *Fus*<sup>ΔNLS/+</sup> mice and ALS patients.

1538 **B.** Cluster dendrogram showing the gene modules identified in human ALS patients and  
1539 *Fus*<sup>ΔNLS/+</sup> mice.

1540 **C-D.** UMAP gene network of the selected modules, each dot represents individual gene which  
1541 size is proportional to its importance (signed kME). The FUS regulon displays a high degree  
1542 of co-expression in mice which is conserved in ALS patients.

1543 **E.** Bar graphs showing correlation of each module to ALS phenotype and directionality in mice  
1544 and human. Dashed lines highlight correlation with FDR<0.05 (Benjamini-Hochberg  
1545 correction).


1546 **F.** Histogram bar graphs show GO enrichment of the FUS regulon. Dashed lines highlight GO  
1547 term with FDR<0.05 (Benjamini-Hochberg correction).

1548 **G.** Heatmap shows eigengene of the FUS regulon across all cell types in *Fus*<sup>ΔNLS/+</sup> mice.  
1549 Wilcoxon rank-sum test with Bonferroni correction \**p*< 0.05/19 (number of cell types). Dot plot  
1550 shows FUS regulon eigengene in L5-IT neurons of *Fus*<sup>ΔNLS/+</sup> mice (Wilcoxon rank-sum test with  
1551 Bonferroni correction \**p*=0.00024)

1552 **H.** Heatmap shows FUS regulon eigengene across all cell types in ALS patients. Wilcoxon  
1553 rank-sum test with Bonferroni correction \**p*< 0.05/21(number of cell types). Dot plot shows

1554 eigengenes expression in L5-PT neurons of Fus<sup>ΔNLS/+</sup> mice (Wilcoxon rank-sum test with  
1555 Bonferroni correction p=0.040)  
1556 **I.** Eigengenes expression of the FUS regulon upon downregulation of 217 different RNA-  
1557 binding proteins and ranked according to effect sizes.  
1558 **J.** Violin plot showing FUS regulon eigengene expression in iPSC-derived motoneurons  
1559 treated with TDP43 shRNA (one-way ANOVA:  $F_{\text{group}}=31.39$ , \*\*p=0.0025).  
1560 **K.** Violin plot showing FUS regulon eigengene expression in TDP43<sup>-</sup> nuclei from FTLN patients  
1561 (one-way ANOVA:  $F_{\text{group}}=21.14$ , \*\*\*p=0.000613).  
1562

1563



1564

1565 **Figure 3: molecular, histological and electrophysiological consequences of adult**  
1566 **mislocalization of FUS in cortical projection neurons.**

1567 **A.** Scheme of the experimental design. Cortical projection neurons show normal nuclear FUS  
1568 until tamoxifen administration (TM) at 6 weeks of age. After this age, FUS is permanently  
1569 mislocalized in the cytoplasm of these neurons, but not in other cell types.

1570 **B.** Representative immunoblot analysis of FUS protein extracted from the frontal cortex,  
1571 predicted molecular weights (MW) in kilodalton (kDa) are shown on the left. SOD1, mostly  
1572 found in the cytoplasm, and HDAC1 exclusively found in the nucleus, were used as control of  
1573 the purity of extracts. Two antibodies for FUS, targeting either the N-terminal part of FUS or  
1574 the NLS (in C-terminal) were used.

1575 **C.** Quantification of FUS immunoreactive bands in cytoplasmic fractions relative to control mice  
1576 (two-tailed Mann-Whitney test: \* $p=0.0127$  and \*\* $p=0.0013$ ).

1577 **D.** Representative widefield images of the immunofluorescent staining of cortical neurons in  
1578 the frontal cortex of 4-month-old mice. GFP and NeuN staining was used to identify neurons  
1579 (NeuN) recombined (GFP). The FUS antibody used here targets the N-terminal part of FUS,  
1580 we observed a clear FUS cytoplasmic mislocalization in cortical neurons of Thy1<sup>CRE-ERT2</sup>/  
1581 FUS<sup>exon15</sup> mice.

1582 **E.** FUS regulon eigengene expression in prefrontal cortex of Thy1<sup>CRE-ERT2</sup>/  
1583 FUS<sup>exon15</sup> and control mice 3 months after TM (two-tailed t-test:  $T=-3.6$ , \* $p=0.013$ ).


1584 **F.** Scheme of the experimental design for ECoG recording.

1585 **G.** Assessment of spikes events (defined as an event higher than a window discriminator of 4  
1586 times the baseline standard deviation calculated from control mice) at 12 and 20-weeks of age  
1587 in Thy1<sup>CRE-ERT2</sup>/  
1588 FUS<sup>exon15</sup> and control mice. Thy1<sup>CRE-ERT2</sup>/  
1589 FUS<sup>exon15</sup> mice show a number of events two times greater than control mice at 12 weeks (two-tailed Mann-Whitney test;  
1590 \*\* $p=0.0079$ ), and five times greater at 20 weeks two-tailed Mann-Whitney test; \*\* $p=0.0079$ ).  
1591 Cortical activity alteration in transgenic mice significantly increases over time (two-way  
1592 ANOVA:  $F_{\text{time}}=146.7$ ,  $p<0.0001$ ) depending on the genotype (two-way ANOVA:  $F_{\text{genotype}}=455.4$ ,  
1593  $p<0.0001$ ).

1594 **H-K.** Neurodegeneration characterization. **H.** 10 slices per mouse in the frontal cortex or in the  
1595 motor cortex were selected for counting. **I.** Representative widefield images of the  
1596 immunofluorescent staining of cortical neurons in the frontal cortex of 4-month-old mice. NeuN  
1597 staining was used to identify and count neurons in the upper layers (mainly layer 2-3 and 5).

1598 **J.** We highlighted a significant decrease in the number of neurons in the frontal cortex of the  
1599 transgenic mice (nested t-test: \*\*  $p=0.0086$ ) and **K.** in the motor cortex of those (nested t-test:  
1600 \*\* $p=0.0242$ ).

1601 Results are expressed as mean  $\pm$  SEM, control mice are represented in black and Thy1<sup>CRE-</sup>  
1602 <sup>ERT2</sup>/  
1603 FUS<sup>exon15</sup> in blue. **C.** Study of FUS mislocalization,  $n = 6$  for control mice and  $n = 8$  for  
1604 Thy1<sup>CRE-ERT2</sup>/  
1605 FUS<sup>exon15</sup> mice (t-test: \* $p=0.013$ ). **E.** Study of FUS regulon.  $n = 5$  for control mice and  $n = 5$  Thy1<sup>CRE-ERT2</sup>/  
1606 FUS<sup>exon15</sup> mice (t-test: \* $p=0.013$ ). **F.** Study of cortical activity,  $n = 5$  for control mice and  $n = 5$   
1607 Thy1<sup>CRE-ERT2</sup>/  
1608 FUS<sup>exon15</sup> mice. **I-K.** Study of neurodegeneration,  $n = 5$  for control mice and  $n = 4$   
1609 Thy1<sup>CRE-ERT2</sup>/  
1610 FUS<sup>exon15</sup> mice.



1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630

**Figure 4: FUS mislocalization in adult neurons leads to ALS-related behavioral and cognitive impairment.**

**A.** Scheme of the experimental design.

**B-C.** Nesting abilities assessment of *Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup>* and control mice. **B.** Score attributed to the nests built in a 24h period starting with 3 g of pressed cotton pieces. We observed that transgenic mice construct nest that are less complicated than the one performed by control mice (two-tailed Mann-Whitney test:  $*p=0.030$ ). **C.** Mass of pressed cotton pieces which were found untorn after 24h. The mass of untorn cotton pieces was significantly higher for *Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup>* than for control mice (two-tailed Mann-Whitney test:  $*p=0.045$ ), highlighting difficulties to plan and/or execute the successive steps involved in nesting.


**D-F** Sociability and social memory assessed using 3 chamber test. **D** During the first 3 trials, we measured the time spent contacting an empty cage or a cage with a mouse (mouse) while during the fourth trial, an unknown mouse is introduced (novel mouse) and allowed to assess the innate attractivity of mouse for novelty. Three-way ANOVA analysis showed a decrease of interest over time ( $F_{\text{time}}=8.217$ ,  $p=0.0008$ ), a higher interest for the mouse than the empty box ( $F_{\text{boxes}}=157.6$ ,  $\#p<0.0001$ ) and a difference between genotype ( $F_{\text{genotype}}=4.075$ ,  $*p=0.0488$ ). **E.** Social memory evaluation by presenting a mouse already met (during trial 1-3, i.e. Known mouse) and a novel mouse. The contacting time of *Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup>* mice with novel mice was significantly lower compared to those of control mice (two-way ANOVA:  $F_{\text{genotype}}=14.39$ ,  $***p=0.0006$ ). Sidák's multiple comparisons test indicated significant higher exploration of

1631 novel mice in comparison to the known one in control mice (###  $p < 0.0001$ ). This is not the  
1632 case for Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup> mice ( $p = 0.8783$ ). **F.** The recognition index, computed as the  
1633 contacting time with novel mouse divided by the total contacting time, was significantly  
1634 decreased compared to those of control mice (two-tailed Mann-Whitney test:  $*p = 0.035$ ). When  
1635 we compared this recognition index to chance level (placed at 50 and indicated by the  
1636 horizontal dotted line), we observed that only control mice presented an index higher than  
1637 chance level (one sample t-test: control mice  $\$p < 0.0001$  and Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup>,  
1638  $p = 0.2233$ ).

1639 **G-H.** Social alteration assessed in another paradigm, resident intruder test. We placed in the  
1640 tested mouse cage an intruder and assess for 5 min the total contacting time (**G**) and the total  
1641 number of contact (**H**). We confirmed the social alteration observed in Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup>  
1642 as they spent less time contacting the intruder than the control mice (two-tailed Mann-Whitney  
1643 test:  $*p = 0.0317$ ) and showed a lower number of total interactions (two-tailed Mann-Whitney  
1644 test:  $**p = 0.0011$ ).

1645 **I-J.** Short-term (10 min) and long term (24hours) object recognition memory. **I.** We did not  
1646 observe any short-term object memory alteration (two-tailed Mann-Whitney test:  $p = 0.662$ ).  
1647 Both groups spent more time than chance level (indicated by the horizontal dotted line)  
1648 exploring the novel object (one sample t-test:  $\$p = 0.011$  for control mice and  $\$\$p = 0.0058$  for  
1649 Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup> mice). **J.** Long-term (10 min) object recognition memory is not affected  
1650 either (two-tailed Mann-Whitney test:  $p = 0.345$ ). Both groups spend more time than chance  
1651 level exploring the new object ( $\$p = 0.016$  for control mice and  $\$\$\$p = 0.0005$  for Thy1<sup>CRE-ERT2</sup>/  
1652 Fus<sup>exon15</sup> mice).

1653  
1654 Results are expressed as mean  $\pm$  SEM, control mice are represented in black and Thy1<sup>CRE-</sup>  
1655 <sup>ERT2</sup>/Fus<sup>exon15</sup> in blue. **D-F.** Study of 3 sociability in 3 chamber test,  $n = 9$  for control mice and  
1656  $n = 10$  for Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup> mice. **G-H** Study of sociability in resident intruder test,  $n = 12$   
1657 control mice and  $n = 11$  for Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup> mice. **I-J** Study of object recognition,  $n = 6$   
1658 control mice and  $n = 8$  for Thy1<sup>CRE-ERT2</sup>/Fus<sup>exon15</sup> mice.  
1659



**Figure 5: FUS mislocalization and downregulation of FUS regulon in vulnerable neurons of patients with ALS and cognitive impairment**

**A.** Representative photomicrographs of *C9ORF72* human post-mortem tissue taken at 10x (top panel) and 40x magnification with optical zoom (middle and lower panels) demonstrating DAB immunohistochemical staining for FUS protein in BA39 (language brain region). These cases had undergone ECAS testing during life, evaluating language function of this brain region, and based on clinically approved cut offs cases were classified as affected (ECAS score  $\leq 26$ ) or unaffected (ECAS score  $> 26$ ). Black arrowheads indicate nuclear pathology, and white arrowheads indicate cytoplasmic pathology within layers III and V of the cortex.


**B-C.** Cell counts were performed by counting the number of cells affected by cytoplasmic pathology (B) or nuclear pathology (C) in 10 randomly assigned regions of interest (1.5 mm<sup>2</sup>) in three cases for each group. Cell counts were performed by a pathologist who was blinded to case and demographic data. ALS cases with normal language function are plotted in yellow and with language dysfunction plotted in red. Each case is plotted demonstrating the variability between and within cases.

**D.** Heatmap showing cell-type specific expression of L5-ET marker genes in 9 excitatory neuron subclasses spanning four different tissues (BA4,BA9,BA44 and BA46).

**E.** Uniform manifold approximation and projection (UMAP) UMAP plot projecting gene expression from 287,275 excitatory neurons colored by subclasses and density plot showing the expression profile of L5-ET top marker genes (*ADRA1A*,*POU3F1*,*VAT1L* and *SULF2*) in

1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681

1682 L5-ET subgroups and L5-ET subtypes top marker genes (*NETO1*, *SERPINE2*, *THSD4* and  
1683 *GRIN3A*)  
1684 **F.** UMAP plot colored by sampled tissue show selective regional presence of L5-ET subgroups  
1685 across motor areas (BA4) and prefrontal area of the cortex (BA9, BA44, BA46).  
1686 **E.** UMAP plot split according to diagnosis show a reduction in L5-ET neurons.  
1687 **H.** Bar plot showing proportion of each excitatory neurons subclass sampled across all donors  
1688 and showing a reduction in L5-ET neurons in ALSci patients compared to ALS and HC (inset  
1689 on the right). The lower panel shows results of a permutation-based test identifying L5-ET  
1690 neurons as significantly depleted in ALSci patients (FDR<0.05 & log<sub>2</sub> Fold difference <-0.58).  
1691 **I.** Heatmap displays FUS regulon expression across major subclasses of excitatory neurons  
1692 in controls (HC), ALS and ALSci patients. A significant decrease is observed in L5-ET neurons  
1693 in ALSci compared to controls (Wilcoxon rank sum test Bonferroni adjusted \*\*p=0.007) and in  
1694 ALS compared to ALSci patients (Wilcoxon rank sum test Bonferroni adjusted \*\*p=0.044).  
1695 \*Adjusted-p <0.05 vs HC, # Adjusted-p <0.05 vs ALS. The violin plot on the right shows FUS  
1696 regulon expression difference in L5-ET neurons of ALSci compared to controls (Wilcoxon rank  
1697 sum test Bonferroni adjusted \*\*p=0.002) and ALS (Wilcoxon rank sum test Bonferroni adjusted  
1698 \*p=0.029) but not between ALS and HC (Wilcoxon rank sum test Bonferroni adjusted p=0.051).  
1699 **J.** Unsupervised clustering of ALS donors (n=36) screened for cognitive impairment shows a  
1700 clear separation between ALS patients (n=22) and ALSci patients (n=14) and heterogeneity in  
1701 clinical scores. Heatmap displays clinical score across 4 ECAS domains that are ALS specific  
1702 (Executive, Language and Verbal Fluency) and non-specific (Memory). Overlay heatmaps  
1703 show FUS regulon expression across donors, TDP43 burden, disease duration and genetic  
1704 burden of rare and common variants associated with neurodegenerative disease-associated  
1705 dementia.  
1706 **K.** Scatter plot shows FUS regulon expression correlation with clinical ALS specific score  
1707 (R<sup>2</sup>=0.32, p=0.051) and ECAS total score (R<sup>2</sup>=0.326, \*p=0.048).  
1708 **L.** Corrplot displays strong correlation across clinical subscore across individuals and a  
1709 significant correlation of the FUS regulon expression with executive function in BA46  
1710 (R<sup>2</sup>=0.60, \*p=0.017) but not with language in BA44 (R<sup>2</sup>=0.37, p=0.26) illustrated in scatter plots  
1711 on the right.  
1712 **M.** Strategy to relate genetic burden of dementia to FUS regulon expression and cognitive  
1713 impairment.  
1714 **N.** Violin plot shows a significant reduction of the ECAS total score in ALS patient with high  
1715 genetic burden (>=2 screened missense variants per patient) vs low (< 2 screened missense  
1716 variants per patient) (Wilcoxon rank sum test \*p=0.034).  
1717 **O.** Dot plots across patients colored by diagnosis shows an increase burden of the number of  
1718 genetic variation observed per individual in known genes and its association with clinical  
1719 subscores.  
1720 **P.** Scatter plot shows FUS regulon expression inverse correlation with genetic burden across  
1721 donor (R<sup>2</sup>=-0.39, \*p=0.034).  
1722



**Figure 6: FUS regulon is enriched in ALS/FTD heritability and prioritizes FBXO16 as a novel risk factor for ALS associated with behavioral impairment.**

**A.** Strategy to characterize heritability through integration of GWAS with the FUS regulon. Each gene in the FUS regulon was mapped to the associated TSS and/or enhancer through single nuclei ATACseq (snATACseq) and linkage disequilibrium score regression computed as described previously

**B.** Dots indicate enrichment and 95% confidence interval computed from LD-score regression. Two-sided p-values were derived from linear regression in LDSC analysis. \* Indicates significance after Bonferroni correction  $p < 0.05/12$ . Results indicate enrichment for ALS-GWAS  $*p = 1.07 \cdot 10^{-24}$  and the FUS regulon  $*p = 1.3 \cdot 10^{-9}$  in ALS heritability but no significant enrichment for randomly samples set of genes ( $p > 0.05$ ).

**C.** Genetic risk factors for ALS, ALS-FTD and FTD were overlapped with the FUS regulon. Venn diagram show overlap between each group with a significant overlap between ALS-FTD gene and FUS regulon (Fisher's exact test  $p = 2.2 \cdot 10^{-06}$ ) but not with ALS only (Fisher's exact test  $p = 0.054$ ) or FTD only (Fisher's exact test  $p = 0.33$ ).


**D.** Strategy to perform GWAS of ALS associated with cognitive (ALS-ci) or behavioral impairment (ALS-bi). Whole genomic sequencing from ALS patients were filtered for SNPs with minor allele frequency above 5% ( $MAF > 0.05$ ). WGS were then filtered based on gene overlap with FUS regulon genes leading to 131,202 SNPs used for GWAS.

**E.** Quantile-Quantile plot depicting on x-axis the  $-\log_{10}$  of expected p value versus the actually measured p values from generalized logistic regression for 131,202 SNPs association with ALS-ci. Genome-wide correction for multiple testing was set at  $P < 1 \times 10^{-6}$ . Highlighted SNP in red reaches genome-wide significant ( $p = 5.44 \cdot 10^{-07}$ ) and is located in the FBXO16 gene.

**F.** Quantile-Quantile plot depicting on x-axis the  $-\log_{10}$  of expected p value versus the actually measured p values from generalized logistic regression for 131,202 SNPs association

1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748

1749 with ALS-bi. Genome-wide correction for multiple testing was set at  $P < 1 \times 10^{-6}$ . Highlighted  
1750 SNP in red reaches suggestive significance ( $p=5.08 \cdot 10^{-5}$ ) and located in *WWOX* gene.  
1751 **G.** Forest plot display per-GWAS association of rs11991627 (*FBXO16*) and rs12324967  
1752 (*WWOX*) in ALS-ci and ALS-bi. Odds ratio (OR) values and 95% CI for each cohort are  
1753 depicted in different color. The graphs display the means and 95% confidence interval.  
1754 **H.** Locus zoom plot showing the SNP (+/- 500KB) rs11991627 (*FBXO16*) association with  
1755 ALS-bi. Red dashed lines show the genome-wide significant SNP at a p-value  $< 6 \cdot 10^{-7}$  and  
1756 colored dots represent LD with the lead variant (red diamond). **I.** Violin plots shows behavioral  
1757 score in rs11991627 carriers of homozygous reference allele ( $n=139$ ) compared to  
1758 heterozygous carriers ( $n=104$ ) (One-way ANOVA  $F_{\text{genotype}}=14.26$ ,  $p=1.31 \cdot 10^{-6}$ , Tukey's post-  
1759 hoc  $**p=2.58 \cdot 10^{-3}$ ) and to homozygous carriers ( $n=25$ ) (Tukey's post-hoc  $****p=5.67 \cdot 10^{-6}$ ).  
1760  
1761



**Figure 7: *FBXO16* PTV carriers have behavioral deficits associated with fronto-temporal atrophy and increase plasmatic expression of NEFL and GFAP.**

**A** Strategy to characterize *FBXO16* PTV carriers in the UK Biobank, and numbers of individuals included. *FBXO16* PTV carriers (n=231) were screened for symptoms associated with cognitive or behavioral deficits among 460,312 individuals of European ancestry. We then evaluated alteration of the brain structure using diffusion and T1 structural MRI from *FBXO16* PTV carriers (n=13) and 37,817 non-carriers controls individuals. Finally, we have used large-scale proteomics data from the UK-Biobank to test whether *FBXO16* PTV carriers (n=14) show significant alteration in major biomarkers when compared to age and sex-matched controls (n=21,604). Levels of different proteins were compared to incident diseased cases diagnosed with Alzheimer's dementia (n=642), ALS (n=198), FTD (n=70) and Vascular dementia (n=161).

**B.** Logistic regression analysis testing whether *FBXO16* PTV carriers' status predict UK-Biobank associated symptoms and signs involving cognition, perception, emotional states and

1762  
1763

1764

1765

1766

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777 behavior. Forest plot shows significant association of *FBXO16* genotype with R45 category  
1778 (Logistic regression Beta coefficient = 1.22; (0.81-1.64), \*p=0.0030). \*Significance is set at p-  
1779 values < 0.05 / 6. A significant association is observed between *FBXO16* genotype and two  
1780 R45 subcategory which are hostility (Beta coefficient = 2.92, (1.91-3.92), \*p=0.0037) and  
1781 nervousness (Beta coefficient = 2.76, (1.75-3.77), \*p=0.006) and a suggestive association with  
1782 apathic behavior (Beta coefficient = 0.80, (0.46-1.14), p=0.018). \*Significance is set at  
1783 Bonferroni corrected p-value < 0.05 / 6 = 0.008.

1784 **C.** Heatmap depicts  $-\log_{10}(p)$  obtained from generalized linear model testing whether *FBXO16*  
1785 genotype is a predictor of IDPs obtained from diffusion MRI imaging of *FBXO16* carriers (n=13)  
1786 and non-carriers (n=37,817). GLM p-values are depicted for the fractional anisotropy and axial  
1787 diffusivity for both hemispheres and each of the white matter tracts. A significant association  
1788 is observed between *FBXO16* genotype and a decrease FA of the genu of the corpus callosum  
1789 (Beta = -0.03 (-0.048,-0.012),\* adjusted-p =0.041) and a decrease AD of the left uncinate  
1790 fasciculus (Beta coefficient =  $-6.17 \cdot 10^{-05}$  ( $-9.53 \cdot 10^{-05}$ ,  $-2.8 \cdot 10^{-05}$ ), \*adjusted-p=0.337).

1791 **D-F.** Heatmap shows the percentage of each of the 31 structures from the Desikan-Killiany  
1792 cortical parcellation atlas which is connected to the nine major white matter tracts in *FBXO16*  
1793 PTV carriers and non-carriers. We observe a decrease in the percentage of the structure  
1794 connected through the left uncinate fasciculus to the pars orbitalis (BA47), the pars-triangularis  
1795 (BA45) and the rostral-middle frontal (BA46). Dashed rectangles. The number of tracts from  
1796 the left uncinate fasciculus connecting to BA47, BA45 and BA46 is significantly decreased in  
1797 *FBXO16* carriers compared to non-carriers (unpaired t-test: t=2.16, \*p=0.045). Also, we  
1798 observed a lower proportion of highly connected tracts of the uncinate fasciculus to BA44,  
1799 BA45, and BA47 in *FBXO16* PTV carriers when compared to non-carriers (Fischer's exact test:  
1800 X-squared = 4.576, df = 1, \*p = 0.032).

1801 **G.** Illustration shows the Z-score differential gray matter area and volume. Unbiased brain-  
1802 wide cluster correlation analysis reveals a significant decrease in left gray matter area located  
1803 on the frontal region in the pars triangularis (BA45) and the rostral medial frontal region (BA46).  
1804 Region-of-interest reveals a significant decrease in the left pars triangularis gray matter area  
1805 (unpaired-t test: t=3.24, \*\*p=0.0047) and volume (unpaired-t test: t=3.33, \*\*p=0.0036).

1806 **H.** Volcano plot shows a significant association between increase GFAP (Beta coefficient =  
1807 0.332, adjusted-p=3.25.10<sup>-05</sup>) and NEFL (Beta coefficient = 0.337, adjusted-p=1.96.10<sup>-06</sup>)  
1808 protein levels in the plasma with incidence of FTD. Forest plot display association between  
1809 GFAP and NEFL levels with dementia subtypes which significant for Alzheimer's disease  
1810 (GFAP-Beta coefficient = 0.29 , \*\*\*p=3.38.10<sup>-49</sup>; NEFL- Beta coefficient = 0.17 , \*\*\*p=1.08.10<sup>-23</sup>),  
1811 vascular dementia (GFAP-Beta coefficient = 0.22 , \*\*\*p=5.45.10<sup>-06</sup>; NEFL- Beta coefficient  
1812 = 0.16 , \*\*\*p=8.32.10<sup>-04</sup>). Only a significant association of NEFL with ALS (NEFL- Beta  
1813 coefficient = 0.14, \*\*p=3.17.10<sup>-03</sup>) but not with GFAP (NEFL- Beta coefficient = -0.003, p=0.92)  
1814 In *FBXO16* carriers a significant association is observed for NEFL (NEFL- Beta coefficient =  
1815 0.27, \*\*p=0.0047) and trend for GFAP (GFAP- Beta coefficient = 0.19, p=0.085). Violin plot  
1816 show a significant increase in mean GFAP protein expression (D-cohen = 0.47; one-tailed  
1817 \*permuted-p = 0.027) and NEFL (D-cohen = 0.67; one-tailed \*\*permuted-p = 0.0023) in  
1818 *FBXO16* PTV carriers.